

Cytokinetics®

PERFORMING WITH PURPOSE

CONTENTS

About this report: In our fourth annual Corporate Responsibility Report, we share information on progress and continuing activities related to corporate responsibility and highlight advancements of our environmental, social and governance priorities that contribute to the success of our company. Unless otherwise noted, all performance reporting covers January 1, 2025 to December 31, 2025. This report is not a comprehensive description or representation of all Cytokinetics corporate responsibilty activities at that time. All financial information is reported in United States (U.S.) dollars. Information on documents filed with the Securities and Exchange Commission (SEC), such as our annual Form 10-K, can be found at **www.cytokinetics.com**.

our mission

To bring forward new medicines to improve the healthspan of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

A MESSAGE FROM OUR CEO

When musicians take the stage, each brings individual skill and dedication. But it is only when they perform in unison that the music reaches its full potential. Performing with Purpose reflects how Cytokinetics approached 2025—as one organization, aligned around a shared mission, each team playing its part to create something meaningful together.

This year marked a defining moment for Cytokinetics. In December 2025, MYQORZO™ (*aficamten*) became our first commercial medicine with approval from the U.S. Food and Drug Administration. That momentum extended globally, with approval from the China National Medical Products Administration and a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency, positioning MYQORZO for potential authorization in the European Union in early 2026*. This milestone represents the culmination of years of bold, trailblazing research in muscle biology and stands as a testament to the strength of our science and the perseverance of patients, healthcare professionals, advocates, partners and employees who made it possible. It was a historic moment for our company and for the patients we serve, as we fulfill our promise to translate our science into medicines that may make a meaningful difference in patients' lives.

Reaching this milestone required extraordinary preparation. Throughout the year, teams across Cytokinetics worked tirelessly and in close coordination to prepare for this inflection point. While engaging with regulators during review, we simultaneously advanced commercial readiness across functions including patient support, distribution, sales and medical affairs. In 2025, we welcomed our first-ever Cardiovascular Account Specialist team, expanded our capabilities across Europe, opened a new office in Dublin, grew our presence in Radnor and South San Francisco and laid the groundwork for expansion in Zug, Switzerland.

We also introduced our Vision 2030 corporate strategy in 2025, articulating our ambition to become the leading muscle-focused specialty biopharma company dedicated to meaningfully improving patients' lives through global access to innovative medicines. To galvanize this journey, we launched Flexing Our Muscles, an initiative centered on purpose, execution and synchronicity. It is about activating our collective strength, recognizing innovation and collaboration, and rising together—a spirit exemplified by colleagues recognized as Muscle Mavericks throughout the year.

Science remained at the heart of everything we do. In 2025, we shared important new data, including the results of MAPLE-HCM, a Phase 3 clinical trial demonstrating the superiority of *aficamten* to metoprolol on exercise capacity in patients with obstructive HCM—findings that may help reshape standards of care. We continued to advance clinical research across our pipeline, completing enrollment in ACACIA-HCM, progressing pediatric and extension studies, advancing COMET-HF and initiating AMBER-HFpEF. At the same time, we strengthened quality systems, governance and clinical trial integrity as we transitioned into a commercial-stage company.

Patients continue to guide our work. This year, we launched the HCM Champions program to deepen our ability to listen and learn from people living with HCM, helping inform how we serve patients beyond the clinic. We also expanded efforts to improve access to disease information through tools like EARTH-HCM, an online public health education platform, reinforcing our commitment to equitable awareness and education.

Our culture proved essential to this progress. Guided by our We > Me mindset and values-based leadership, employees demonstrated resilience, collaboration and integrity during a year of rapid growth. We strengthened compliance systems, expanded training, established AI governance and invested in leadership development and mentorship.

As our footprint has expanded, so too has the structure of this report. What began as three pillars has evolved into six interconnected sections—Science, Patients, Culture, Integrity, Communities and Operations—reflecting the breadth of our impact and responsibilities to stakeholders.

We remain humbled by the opportunity to serve patients and contribute to healthier communities. While 2025 will be remembered as a milestone year, it also reflects a beginning for us. With purpose as our guide and collaboration as our strength, we look ahead with confidence and resolve to continue performing together—and performing with purpose.

Thank you for your continued support.

Robert Blum
President & Chief Executive Officer
Member, Board of Directors

* MYQORZO was approved by the European Commission in February 2026.

ABOUT CYTOKINETICS

Cytokinetics is a biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class inhibitors as potential treatments for people with debilitating diseases in which muscle performance is either compromised or declining.

Since operations began in 1998, we have developed unparalleled expertise that keeps us at the forefront of drug discovery and development for diseases impacting muscle performance with more than 170 publications, over 100 clinical trials and numerous issued patents. With a corporate headquarters in South San Francisco, California, Cytokinetics is currently operating in eight countries and has offices in Radnor, Pennsylvania and outside the U.S. in Dublin, Ireland and Zug, Switzerland.

Areas of Focus

Cytokinetics' research and development focuses on impacting the mechanics of muscle function with investigational medicines that may improve muscle strength, power or performance. We aspire to develop new medicines that improve patient outcomes for people living with debilitating diseases of muscle dysfunction.

VISION2030

Empowering Muscle, Empowering Lives

To be the leading muscle-focused specialty biopharma company intent on meaningfully improving the lives of patients through global access to our innovative medicines

INNOVATION
Advance 2 approved products across 3 indications and 10 NMEs in our pipeline

IGNITION
Achieve broad access and rapid use of our medicines in >15 countries throughout North America and Europe

IMPACT
Reach >100,000 patients globally with our medicines

INSPIRATION
Foster a patient-centric culture with emphasis on equitable access

INGENUITY
Extend leadership in muscle biology deploying multiple therapeutic modalities

Cytokinetics' Vision 2030 outlines five-year strategic objectives to propel our mission.

at-a-glance

$88.0M	$416M	670+	170+	6	4
REVENUE IN 2025	R&D INVESTMENT IN 2025	EMPLOYEES	PUBLICATIONS	CLINICAL TRIAL PROGRAMS	OFFICE LOCATIONS

Culture and Values

Cytokinetics' award-winning culture is driven by four values that guide everything we do, every day. They are:

Patients are our North Star

- We seek to understand our patients' journeys, and proactively embed their needs in our goals, priorities, business and community partnerships
- We keep the patient front and center in all we do; all actions and decisions are in service of the patient and their caregivers
- We advocate for the patient through our engagement in patient-centric activities like fundraising events, public policy initiatives, volunteering and education

Science is in our soul

- We are committed to robust scientific thinking, grounded in integrity and critical thinking, and not polluted by politics or divisiveness
- We invite healthy debate, test hypotheses, encourage independent thought and courageously explore the unknown—all in service of improving patient health and humanity
- We are problem solvers—we push boundaries and think beyond the norm to come up with out-of-the-box solutions that make a difference

We > Me

- We are stronger as a team, valuing the power of diversity and rising together as one
- We insist on transparency, collaboration and feedback
- We champion integrity, ethics, doing the right thing and being our best selves

Make it happen

- We are tenacious and resilient, confidently navigating ambiguity to deliver results
- We demonstrate courage by taking calculated risks, failing fast and recovering quickly
- We hold ourselves accountable for our actions without excuses or blame

flexing our muscles

Working together to meet the moment

Flexing Our Muscles is a company-wide unifying campaign designed to strengthen organizational readiness at a pivotal stage of growth and transformation. As the company advances toward its Vision 2030 goals and prepared for its first-ever approved commercial launch, the initiative unites more than 500 employees across functions to align around shared priorities, evolving ways of working with a heightened responsibility to patients and communities.

The initiative is built around three integrated strengths:

Strength in Purpose (Heart) grounds the organization in why the work matters, reinforcing a shared commitment to delivering meaningful impact for patients.

Strength in Execution (Mind) sharpens how work gets done, emphasizing rigor, accountability, and continuous improvement as the company scales.

Strength in Synchronicity (Heart–Mind) aligns teams across the enterprise, enabling collaboration, adaptability, and coordinated progress.

By investing in its people and culture, the company is building a resilient, values-driven organization prepared not only for a landmark product launch, but for sustained long-term growth.

"Muscle Mavericks embody the innovation, tenacity and collaboration that will carry us forward."

ROBERT BLUM
PRESIDENT & CHIEF EXECUTIVE OFFICER

Flexing Our Muscles is embedded into everyday work life through events, visual touchpoints, branded apparel, and ongoing internal communications. Highlighting 'Muscle Mavericks' provides recognition and reward for those excelling in these strengths.

CORPORATE RESPONSIBILITY GOVERNANCE

We have built a corporate responsibility (CR) governance structure to support accountability for environmental and sustainability matters as the company grows. The Board of Directors provides oversight through the Nominating and Governance Committee.



The Cytokinetics Corporate Responsibility Committee—chaired by our Senior Vice President of Corporate Affairs—includes functional leaders and subject matter experts from across the company including Human Resources; Legal; Medical and Clinical; Facilities; Commercial; Compliance; Patient Advocacy; Global Supply Chain and Technical Operations; Regulatory; and Research and Development (R&D). The CR Committee provides regular updates to the CEO and Board about our corporate responsibility activities, priorities and overall strategy.

To inform our corporate responsibility planning and disclosures, we look to our stakeholders and third-party frameworks, including Sustainability Accounting Standards Board (SASB) guidelines for our industry and the Global Reporting Initiative (GRI). We have included an index of responsive disclosure with SASB and GRI at the end of this report.

Materiality

Our sustainability materiality matrix, most recently updated in 2024, identifies topics most relevant to our business and stakeholders. Developed through industry benchmarking, stakeholder interviews, and engagement with senior leadership and the Board, it informs priority-setting, corporate responsibility disclosures, and decision-making.



Alignment with the United Nations Sustainable Development Goals

The United Nations Sustainable Development Goals (SDGs) are seventeen global objectives aimed at addressing challenges such as poverty, health and climate change. We reference select SDGs to illustrate how our corporate responsibility priorities align with broader global sustainability topics relevant to our business. Below are some of the ways we are working toward the goals most relevant to our business.

- Improving health outcomes is at the heart of Cytokinetics' mission, propelling our research and innovation to address unmet needs
- Our patient-centric approach of listening to and learning from those living with debilitating diseases guides us in developing potential treatments
- Our wellness focus for employees and associated benefits support their health and well being

- Our inclusion and belonging initiatives and corporate policies are designed to support equitable leadership development and fair compensation practices across the organization
- Cytokinetics supports science education and career opportunities for young people

- For more than 25 years, Cytokinetics has grown steadily, supporting workforce development and long-term employment as the company has expanded
- Cytokinetics' financial stewardship over decades contributes to the economic development and vitality of communities in which we operate

- In our offices and labs, we seek ways to minimize and eliminate waste and resource consumption by examining and optimizing materials and processes
- Our clinical and commercial supply chain is built on strategic partnerships with vendors that are expected to meet defined standards related to quality, ethics, and responsible business practices

An integrated approach

Cytokinetics' approach to corporate responsibility is grounded in collaboration across the organization and reflects how our work is carried out in practice. As the company has grown, our reporting has evolved from three foundational pillars to a six-chapter structure—Science, Patients, Culture, Integrity, Communities and Operations—providing clearer alignment with our expanding footprint and making our disclosures more accessible and easier to navigate.

This integrated framework is supported by cross-functional task forces that bring together diverse expertise to address complex challenges. Examples include collaboration among supply chain, regulatory and quality teams to establish the Dublin Center of Excellence, and the Equity in Cardiovascular Disease working group, which includes representatives from medical affairs, corporate affairs, global commercial, clinical operations, patient advocacy and compliance.

"By working across functions and disciplines, we embed responsibility into how decisions are made—strengthening accountability, advancing impact and ensuring our strategy reflects the needs of all stakeholders."

COLLEEN HEALY
SENIOR DIRECTOR, PROFESSIONAL SOCIETY RELATIONS

2025 HIGHLIGHTS

MYQORZO™ (*aficamten*) was approved by the U.S. Food and Drug Administration for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capac ity and symptoms



The China National Medical Products Administration approved MYQORZO® (*aficamten*) for the treatment of adults with NYHA class II–III oHCM to improve exercise capacity and symptoms

MAPLE HCM

Presented primary MAPLE-HCM (**M**etoprolol vs ***A**ficamten* in **P**atients with **L**VOT Obstruction on **E**xercise Capacity in **HCM**) Phase 3 clinical trial results at ESC Congress 2025 demonstrating superiority of *aficamten* to metoprolol on peak oxygen uptake and five secondary endpoints

The Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion recommending EU marketing authorization for *aficamten* in symptomatic oHCM

Established a Global Supply Chain and Quality Operations Center of Excellence in Dublin to support U.S., Europe and China product launches and enable global scale operations

Hosted the second annual CLIMB Symposium convening scientists and emerging professionals to advance interdisciplinary dialogue in cardiac and skeletal muscle biology

124 **EMPLOYEES IN MENTOR–MENTEE PAIRS DURING INAUGURAL SIX-MONTH CYCLE OF CYTO EXCHANGE, A COMPANY-WIDE MENTORSHIP PROGRAM**

Continued enrolling patients in CEDAR-HCM (**C**linical **E**valuation of **D**osing with ***A**ficamten* to **R**educe Obstruction in a Pediatric Population in **HCM**) evaluating *aficamten* in pediatric obstructive hypertrophic cardiomyopathy, with adolescent enrollment expected into 2026

CEDAR HCM

RECRUITED, HIRED AND ONBOARDED CARDIOVASCULAR ACCOUNT SPECIALISTS WITH RARE DISEASE AND CARDIOVASCULAR EXPERIENCE TO SUPPORT HEALTHCARE PROFESSIONALS AND NEW PATIENT STARTS

FORTUNE BEST WORKPLACES IN BIOPHARMA™ 2025

Cited by Fortune magazine as a "Best Workplace in BioPharma" and "Best Workplace in the Bay Area" for a fourth consecutive year

COMET-HF

Continued conduct of COMET-HF (**C**onfirmation of ***O**mecamtiv **M**ecarbil* **E**fficacy **T**rial in **H**eart **F**ailure), a confirmatory Phase 3 clinical trial of *omecamtiv mecarbil* in patients with severe heart failure with enrollment expected through 2026

Certified as "Great Place to Work" for a fourth consecutive year

Recognized by the San Francisco Business Times as a "Best Place to Work in the Bay Area" for the fifth consecutive year

BPtW

Continued conduct of AMBER-HFpEF (**A**ssessment of CK-586 in a **M**ulti-Center, **B**linded **E**valuation of Safety and Tolerability **R**esults in **HFpEF**), a Phase 2 clinical trial of *ulacamten* in patients with symptomatic heart failure with preserved ejection fraction

AMBER HFpEF

Designed MYQORZO & You™, a comprehensive patient support program paired with the MYQORZO REMS Program to support treatment initiation and ongoing monitoring

LAUNCHED THE HCM CHAMPIONS PROGRAM TO CREATE A SCALABLE, COMPLIANT AND EMOTIONALLY RESONANT WAY FOR PATIENTS, CAREGIVERS AND ADVOCATES TO CONNECT AND ENGAGE WITH EMPLOYEES AND EACH OTHER

ADVANCING RESEARCH TO IMPROVE LIVES

Science is foundational to Cytokinetics' mission and shapes how we operate across the organization—from discovery through clinical evaluation, strategic decision-making and stakeholder education.

Our innovation is rooted in a deep understanding of muscle biology and a commitment to addressing unmet patient needs. In service of our Vision 2030, we are progressing our pipeline by translating causal human biology into targeted, data-driven development programs, supported by new modalities, partnerships and technologies. Quality systems span the full lifecycle, designed to drive consistency, reliability and continuous improvement across clinical and commercial programs. We strive to reflect diverse patient populations in clinical trials, supported by robust oversight to maintain integrity and transparency. By integrating scientific rigor, quality management and ethical conduct at every stage of our research, development and commercial operations, we reinforce trust.

MATERIAL TOPICS

- Rigorous science and innovation
- Diversity in clinical trials

28
NEW RESEARCH PUBLICATIONS

55
SCIENCE PRESENTATIONS

KEY ACCOMPLISHMENTS

- Received approval of MYQORZO™ (*aficamten*) for treatment of oHCM in the U.S. and China and a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency
- Successfully completed global regulatory inspections
- Announced positive results of MAPLE-HCM

2026 PRIORITIES

- File Supplemental New Drug Application (sNDA) for *aficamten* based on MAPLE-HCM
- Advance six ongoing clinical stage programs including three with active enrollment
- Pursue discovery of at least two investigational new drugs (INDs) to enter clinic in 2027
- Develop and enact diversity plans as integral part of clinical trial design

IN THIS SECTION

RESEARCH AND DEVELOPMENT

Our research and development strategy integrates cutting-edge science with patient-centric principles.

Collaboration is a cornerstone of our innovation. Cytokinetics partners with academic institutions, biotechnology companies and patient advocacy groups to accelerate discovery and align our therapies with patient needs. Through our Patient and Caregiver Advisory Councils, we gain invaluable insights into disease impact and treatment priorities, shaping our clinical trial designs and endpoints.

Our commitment to innovation extends into every phase of development. We employ adaptive trial designs, leverage real-world evidence and develop validated patient-reported outcome measures (PROMs) to evaluate how our therapies improve patients' lives. Transparency and data-driven decision-making guide our pipeline, supporting efficient resource allocation and maximum therapeutic potential.

Advancing a specialty cardiovascular development pipeline

Our deep understanding of muscle biology enables us to develop potential therapies targeting muscle contractility, performance and fatigue. By focusing on the mechanism of muscle dysfunction at a molecular level, we are advancing treatments that address unmet medical needs in cardiovascular diseases. We employ advanced technologies to design small molecule therapeutics that modulate muscle proteins. This approach has led to the development of investigational drugs for conditions like hypertrophic cardiomyopathy (HCM) and heart failure.

AI-enabled discovery

We have begun leveraging artificial intelligence across research functions to enhance productivity, expand ideation and support hypothesis generation. Early applications in chemistry and structure–activity relationship modeling have demonstrated the potential of AI-enabled tools to surface novel insights, accelerate decision-making and free scientists to focus on creative and strategic work.

Empowering ingenuity

Looking ahead, Cytokinetics is intentionally balancing internally generated innovation with external opportunities, guided by clear scientific criteria and responsible capital allocation. We are prioritizing programs that can advance toward clinical entry over the coming years, including continued investment in contractility science and exploration of new modalities such as protein degradation.

Cytokinetics' R&D approach exemplifies how scientific rigor and patient focus can drive meaningful progress. By addressing the root causes of muscle dysfunction and collaborating across disciplines, we are redefining possibilities in muscle biology and advancing therapies with the potential to transform lives.

> "Research sits at both the beginning and the end of our work—driving discovery and preclinical development while also supporting education and collaboration across medical, regulatory and commercial teams."

AJAY CHAWLA
VICE PRESIDENT, BIOLOGY

Publishing our research

Cytokinetics scientists are committed to high scientific and ethical publications standards and to providing our science to the medical and scientific community through peer-reviewed journals and medical forums.

In 2025, Cytokinetics authors and research teams advanced the field with a remarkable body of scientific work, sharing discoveries across clinical, translational and real-word research. This year we achieved 28 manuscripts accepted or published along with 41 abstracts submitted and 55 presentations delivered at major scientific congresses.

These publications contribute to a growing evidence base to help educate physicians about potential treatments. We also publish Plain Language Summaries (PLS) of our trials, written in clear, non-technical language to explain trial designs and outcomes for participants and stakeholders.

View publications at
cytokinetics.com/publications

From Research to Far-Reaching Impact

In December 2025, Cytokinetics reached a defining milestone with the approval of MYQORZO™ (*aficamten*), marking the company's first commercial medicine and the culmination of years of focused scientific effort.

Approved by the U.S. Food and Drug Administration for adults living with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), MYQORZO offers patients a new treatment option designed to improve daily functioning and quality of life. Approval by the China National Medical Products Administration was received in December 2025, followed by approval from the European Commission in February 2026.

For people living with oHCM, symptoms such as shortness of breath, fatigue and limited physical capacity can profoundly affect everyday activities. MYQORZO was developed to address the underlying cause of obstruction in the heart, helping patients feel and function better. Cytokinetics is supporting patients through MYQORZO & You™, a personalized program that provides education, treatment navigation and assistance with insurance and financial support.

"For far too long, we've had few options to address our needs, and the approval of MYQORZO is a long-awaited and major addition to bring new hope to patients living with oHCM."

LISA SALBERG
FOUNDER AND CEO OF THE HYPERTROPHIC CARDIOMYOPATHY ASSOCIATION (HCMA)

In the United States, MYQORZO™ (*aficamten*) is available in 5 mg, 10 mg, 15 mg, 20 mg tablets with access through a Risk Evaluation and Mitigation Strategy (REMS) Program, which includes monitoring requirements for patients and certification for prescribers and pharmacies.

2018
Initiated Phase 1 study of *aficamten*

2020
Initiated REDWOOD-HCM, a Phase 2 clinical trial of *aficamten*

2021
Received orphan drug designation for *aficamten* for the treatment of HCM

Started FOREST-HCM, an open-label extension study of *aficamten* (ongoing)

Announced results of REDWOOD-HCM, a pivital Phase 2 clinical trial of *aficamten* in HCM

2022
Started SEQUOIA-HCM a Phase 3 clinical trial of *aficamten* in oHCM

Began Phase 2 cohort 4 of REDWOOD-HCM clinical trial of *aficamten* in nHCM

2023
Started MAPLE-HCM, a Phase 3 clinical trial of *aficamten* in oHCM

Started ACACIA-HCM, a Phase 3 clinical trial of *aficamten* in nHCM (ongoing)

Announced positive results of SEQUOIA-HCM, the pivotal Phase 3 clinical trial of *aficamten* in oHCM

2024
Initiated CEDAR-HCM, a Phase 3 clinical trial of *aficamten* in a pediatric population with oHCM (ongoing)

FDA accepted New Drug Application for *aficamten* in oHCM

2025
Received FDA Approval of MYQORZO™ (*aficamten*) for the treatment of adults with symptomatic oHCM to improve functional capacity and symptoms

2026
First patients prescribed and ongoing clinical trials of *aficamten*

Science is in Our Soul Day 2025

In October 2025, Cytokinetics held its third annual Science is in Our Soul Day (SIIOSD), celebrating how every department applies scientific thinking to advance the company's mission. The event featured both in-person and virtual poster sessions highlighting work across disciplines, including clinical and pre-clinical research, scientific publication planning, patient centricity, grants and corporate giving.

Participation continued to grow year over year, with virtual slide presentations more than doubling—from eight to eighteen—reflecting the company's commitment to inclusivity for remote employees. Nearly 100 posters were presented, and for the first time, newly hired Cardiovascular Account Specialists joined the afternoon session, strengthening cross-functional connections and welcoming them into Cytokinetics' research-driven culture.

99
POSTERS PRESENTED

18
VIRTUAL POSTERS

"This event provides a unique opportunity for all employees to come together, connect, learn from one another and celebrate the work we do."

NARSIMHA MUNAGALA
ASSOCIATE DIRECTOR, TRANSLATIONAL BIOLOGY

"SIIOSD exemplifies Cytokinetics' commitment to our core values as a company, always keeping science and patients at the forefront of everything we do."

RICKY SIDHU
SENIOR MANAGER, SCIENTIFIC COMMUNICATIONS

Along with poster presentations, the 2025 event included a ribbon-cutting ceremony for a new Discovery Gallery at our South San Francisco office. Part art gallery and part science museum, the new space (shown bottom right) blends artifacts, photos, stories, and digital media into an immersive storytelling experience about Cytokinetics' history.

A COMMITMENT TO MUSCLE-DIRECTED MEDICINES

Cytokinetics has one approved medicine, six clinical-stage programs and ongoing research in muscle function, contractility, energetics and metabolism.

Clinical-stage programs are focused on cardiovascular conditions including: hypertrophic cardiomyopathy (HCM), a progressive condition that causes the heart to thicken and stiffen, eventually limiting its ability to pump blood; and heart failure (HF), a progressive condition in which the heart becomes enlarged, thickened or rigid, hindering its ability to pump blood throughout the body.

> "Our long-term commitment to understanding the basic biology of muscle cell function and our steadfast relationships with patient advocates have inspired us to build a pipeline of disease-modifying drugs to improve patients' lives."

STUART KUPFER, M.D.
SENIOR VICE PRESIDENT, CHIEF MEDICAL OFFICER



*Please see full Prescribing Information, including Boxed WARNING and Medication Guide

**MYQORZO is only approved in the U.S., China and the EU for the treatment of adults with symptomatic oHCM.

Ulacamten, omecamtiv mecarbil and CK-089 are investigational agents and have not been approved for use by any regulatory agency. Their safety and efficacy has not been established.

oHCM: obstructive hypertrophic cardiomyopathy
nHCM: non-obstructive hypertrophic cardiomyopathy
HFpEF: heart failure with preserved ejection fraction
HFrEF: heart failure with reserved ejection fraction
EC: European Commission
sNDA: Supplemental New Drug Application

APPROVED MEDICINE

Aficamten

MYQORZO™ (*aficamten*) is an allosteric and reversible inhibitor of cardiac myosin motor activity.

MYQORZO™ (aficamten) 5·10·15·20 mg tablets

MYQORZO is approved by the U.S. FDA, the China National Medical Products Administration and European Commission for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms in adult patients.

In patients with HCM, myosin inhibition with MYQORZO reduces cardiac contractility and left ventricular outflow tract (LVOT) obstruction. MYQORZO was engineered to achieve a predictable exposure response, rapid onset of action and reversibility.

MYQORZO (*aficamten*) is only approved in the U.S., China and the EU for oHCM.

ONGOING RESEARCH

MAPLE HCM

In May 2025, Cytokinetics announced positive topline results from MAPLE-HCM (**M**etoprolol vs ***A****ficamten* in **P**atients with **L**VOT Obstruction on **E**xercise Capacity in **HCM**), a Phase 3 clinical trial evaluating *aficamten* as monotherapy compared with metoprolol, a commonly prescribed beta blocker, in patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). The study met its primary endpoint, demonstrating a statistically significant improvement in peak oxygen uptake (pVO_2) at Week 24 with *aficamten* compared to metoprolol. *Aficamten* also demonstrated a favorable safety and tolerability profile. MAPLE-HCM enrolled 175 patients in a randomized, double-blind design, with participants eligible to continue into the open-label extension study, FOREST-HCM.

ACACIA HCM

CEDAR HCM

FOREST HCM

Aficamten is also under clinical investigation in ACACIA-HCM (**A**ssessment **C**omparing ***A****ficamten* to Placebo on **C**ardiac Endpoints **I**n **A**dults with Non-Obstructive **HCM**), a Phase 3 clinical trial in patients with non-obstructive HCM (nHCM) and CEDAR-HCM (**C**linical **E**valuation of **D**osing with ***A****ficamten* to **R**educe Obstruction in a Pediatric Population in **HCM**), a Phase 3 clinical trial in a pediatric population with oHCM. *Aficamten* has not been deemed safe or effective for use in either of these patient populations. In addition, *aficamten* is being studied in FOREST-HCM (**F**ollow-up, **O**pen-Label, **R**esearch **E**valuation of **S**ustained **T**reatment with *Aficamten* in **HCM**), an open-label extension clinical study.

EARTH HCM

EARTH-HCM (**E**pidemiology, **A**wareness, **R**eal-world **T**reatment and **H**ealth Outcomes in **HCM**) is an open access, public health education tool developed by Cytokinetics in collaboration with experts from leading research institutions. The interactive online platform uses real-world data to visualize the geographical distribution of HCM in the U.S., offering an innovative, user-friendly way for a wide audience of patients, clinicians, pharmacists, researchers, policy decision-makers and patient advocacy groups to learn about HCM. The resource has served as the basis for a recent **journal publication**, with an update planned for 2026 and the potential to integrate data for regions outside the U.S.

> "EARTH-HCM aims to advance research, uncover knowledge gaps and investigate disparities in care, ultimately promoting more equitable access, not just for our company, but for the entire HCM community."

SANATAN SHREAY, PH.D.
EXECUTIVE DIRECTOR, HEAD OF HEALTH ECONOMICS AND OUTCOMES RESEARCH

WHAT IS HCM?

Hypertrophic Cardiomyopathy

HCM is a genetic disease in which the heart muscle becomes abnormally thick (hypertrophies) and stiffens, eventually limiting its ability to pump blood. This ultimately limits the heart's pumping function, resulting in reduced exercise capacity and symptoms including chest pain, dizziness, shortness of breath or fainting during physical activity.[1,2] An estimated two-thirds of HCM patients have obstructive HCM (oHCM), in which the thickening of the cardiac muscle leads to left ventricular outflow tract (LVOT) obstruction; one-third have non-obstructive HCM (nHCM), in which blood flow is not impacted but the heart muscle is still thickened.

INVESTIGATIONAL MEDICINES

Omecamtiv mecarbil

Omecamtiv mecarbil is an investigational, selective, small molecule cardiac myosin activator, the first of a novel class of myotropes designed to directly target the contractile mechanisms of the heart, binding to and recruiting more cardiac myosin heads to interact with actin during systole. In doing so, *omecamtiv mecarbil* augments the impaired contractility that is associated with heart failure with reduced ejection fraction (HFrEF).

GALACTIC-HF

Omecamtiv mecarbil was the subject of a positive Phase 3 clinical trial, GALACTIC-HF (**G**lobal **A**pproach to **L**owering **A**dverse **C**ardiac Outcomes **T**hrough **I**mproving **C**ontractility in **H**eart **F**ailure), in patients with HFrEF. The magnitude of the treatment effect in a pre-specified subgroup of more than 4,500 patients with heart failure with severely reduced ejection fraction (<30%) was observed to be greater than in the overall drug treated population of GALACTIC-HF.

COMET-HF

Building on the results of GALACTIC-HF, Cytokinetics has initiated COMET-HF (**C**onfirmation of ***O****mecamtiv* ***M****ecarbil* **E**fficacy **T**rial in **H**eart **F**ailure), a confirmatory Phase 3 clinical trial to assess the efficacy and safety of *omecamtiv mecarbil* in patients with symptomatic heart failure with severely reduced ejection fraction. COMET-HF is being conducted in collaboration with Duke Clinical Research Institute (DCRI) and is enrolling 1,800 patients to evaluate the impact of *omecamtiv mecarbil* on extending time to cardiovascular death, heart failure events or advanced interventions such as left ventricular assist device (LVAD) implantation or cardiac transplantation. Participants will receive *omecamtiv mecarbil* or placebo until 850 key events occur. Enrollment began in December 2024 and continued throughout 2025.

WHAT IS HFrEF?

Heart Failure with Severely Reduced Ejection Fraction

Heart failure is a grievous condition that affects more than 64 million people worldwide[3] about half of whom have reduced left ventricular function.[4,5] It is the leading cause of hospitalization and readmission in people age 65 and older.[6,7] By 2029 is it estimated that 2.8 million people in the U.S. will have heart failure with severely reduced ejection fraction[8], characterized as heart failure with reduced ejection fraction (HFrEF) <30%, and 840,000 people will have severely reduced ejection fraction with other features indicative of high risk heart failure.[9] Patients with high risk heart failure with severely reduced ejection fraction account for approximately 60% of all HFrEF hospitalizations, with 35% of patients re-hospitalized within a year.[10,11]

INVESTIGATIONAL MEDICINES

Ulacamten (CK-586)

This investigational, novel, selective, oral, small molecule cardiac myosin inhibitor is designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction (HFpEF).

In preclinical models, *ulacamten* reduced cardiac hypercontractility by decreasing the number of active myosin cross-bridges during cardiac contraction, thereby reducing the contractile force, without effect on calcium transients.

Ulacamten was evaluated in a Phase 1 study assessing the safety, tolerability and pharmacokinetics of single and multiple oral doses of *ulacamten*. *Ulacamten* is now the subject of AMBER-HFpEF (**A**ssessment of CK-586 in a **M**ulti-Center, **B**linded **E**valuation of Safety and Tolerability **R**esults in **HFpEF**), a Phase 2 clinical trial in a subgroup of patients with symptomatic HFpEF with hypercontractility and ventricular hypertrophy.

AMBER HFpEF

WHAT IS HFpEF?

Heart Failure with Preserved Ejection Fraction

HFpEF is a condition where the heart pumps normally but struggles to relax and fill properly, leading to symptoms like shortness of breath, fatigue and swelling in the legs. Unlike other types of heart failure, the heart's pumping ability, measured by ejection fraction, remains normal (≥50%). HFpEF is common in older adults and often linked to conditions like high blood pressure, obesity and diabetes. The stiffened heart muscle cannot relax well, causing increased pressure and fluid buildup. Diagnosis involves tests like echocardiograms and blood biomarkers (e.g., NT-proBNP). Despite the availability of therapies, patient symptoms are not currently well managed.



The Sarcomere: the fundamental unit of muscle contractility

The principal functionality of muscle is rooted in its ability to contract and relax. The foundation for muscle contraction is the sarcomere, found in all muscle cells. Sarcomeres contain a motor protein called myosin, which powers the muscle to contract by "grabbing" onto another protein called actin and "flexing." When the myosin releases the actin, the muscle relaxes. This process is regulated by another protein called troponin.

Sarcomere malfunctions that cause decreased or increased contractility of the muscle play a central role in diseases like heart failure with reduced ejection fraction and HCM, respectively. Therapies with the potential to modulate sarcomere function may improve the lives of patients suffering from these diseases.

Cytokinetics' research is focused to modulating proteins in the sarcomere, the fundamental unit of muscle contraction found within muscle cells. These crucial proteins are the keys to unlocking the potential treatment of diseases that are caused by impaired muscle function.

CLIMB Research Symposium 2025

Cytokinetics hosted its second annual Contemporary Landscapes in Muscle Biology Research Symposium (CLIMB) in May 2025, convening scientists, researchers and emerging professionals at the Mission Bay Conference Center in San Francisco.

The one-day symposium aims to foster collaboration, facilitate networking opportunities and promote interdisciplinary dialogue, with the ultimate goal of driving advancements in the biological understanding and emerging treatment of muscle-related diseases and disorders. CLIMB doubled registration from its inaugural year and featured a program of distinguished expert speakers and novel research posters focusing on innovations in cardiac biology, skeletal muscle biology and emerging treatment modalities in muscle biology. Participants praised the event's scientific caliber and collaborative spirit.

116
ATTENDEES

10
SPEAKERS

14
POSTER PRESENTATIONS

"CLIMB was born out of our vision to bring together key contributors in muscle biology across academia and industry to foster meaningful scientific exchange and showcase novel research."

FADY I. MALIK, M.D., PH.D.,
EXECUTIVE VICE PRESIDENT OF RESEARCH & DEVELOPMENT

"The symposium was fantastic—a testament to Cytokinetics' leadership in innovation and forward thinking. The breadth of speakers was a perfect balance."

ROBIN M. SHAW, M.D., PH.D.
DIRECTOR, NORA ECCLES HARRISON CARDIOVASCULAR RESEARCH AND TRAINING INSTITUTE
PROFESSOR OF MEDICINE, UNIVERSITY OF UTAH

PRODUCT QUALITY AND SAFETY

The Cytokinetics quality assurance program, overseen by the Chief Legal and Administrative Officer, provides a structured framework for training, governance, and performance monitoring to support product quality and patient safety. The activities of our Quality Team span R&D, clinical trials, supply chain and technical operations.

Quality Management System

Our Quality Management System (QMS) is designed to support adherence to global regulations, ICH guidelines and internal standards, as well as assure that our products meet specified identity, strength, purity and safety requirements.

The Cytokinetics Quality Manual is the foundation of our QMS. Employees are expected to complete onboarding and annual training on the quality manual. The quality manual provides guidance on maintaining patient protection and data integrity in clinical trials, clinical and commercial product quality, product safety, compliance and continuous improvement systems and processes.

Our electronic QMS platform includes robust reporting and risk management, supporting a proactive approach to identifying, assessing and controlling deviations with mechanisms for escalating issues to the appropriate level. Our internal audit program includes annual audits for Good Clinical Practice (GCP) and Good Manufacturing Practice (GMP) operations. External partners and vendors must also align with our quality requirements, verified through audits and quality agreements. For clinical trials, we employ continual safety and stringent quality monitoring.

Quality is the responsibility of all personnel, with expectations and requirements across levels from employees and contractors, through senior management. Monthly GCP Compliance Committee meetings, as well as monthly quality forums, facilitate cross-functional discussions on quality issues and ongoing assessment of our QMS. Quarterly Quality Management Review Boards, attended by senior leadership including the CEO and Chief Medical Officer (CMO), provide a platform for regular evaluation of the effectiveness of our QMS, escalation of potential quality issues, and to assess appropriate resource allocation. The CEO is accountable for Cytokinetics' overall adherence to the QMS.

2025 QUALITY HIGHLIGHTS

As Cytokinetics transitioned from a research-focused organization to a commercial-stage company, expectations for compliance, rigor and execution increased significantly. This evolution required heightened accountability at every level. Processes must be consistent, robust, reliable and repeatable; once systems are validated, they must perform without deviation.

With a top priority of achieving readiness to launch a high-quality, compliant product on time, here are some of the ways we advanced quality at Cytokinetics in 2025.

> "We've built a strong quality management framework with a culture of continuous improvement and transparent governance—all to build stakeholder trust and operational excellence."

MEGAN TRUONG
VICE PRESIDENT, QUALITY

- Successfully hosted global regulatory inspections, including those conducted by the FDA, the California Board of Pharmacy and the EMA, as well as inspections at clinical sites across China, the United States and Europe. Each inspection concluded successfully, marking a significant milestone as the company navigated this level of global regulatory oversight for the first time.
- Established the Dublin, Ireland office as a European hub for supply chain, technical operations, and quality. The site houses Cytokinetics' Qualified Persons (QPs), who will release commercial batches globally, and reflects the evolution to a fully integrated global quality system supporting multiple markets. (See **Center of Excellence, page 42**)
- Expanded enterprise quality systems to support global commercialization, including GMP compliance, supplier qualification and capabilities to manage recalls, complaints and quality oversight across regions.
- Enhanced training programs to further embed a culture of quality across the organization. Efforts expanded beyond online policy training to include instructor-led sessions and interactive workshops on GMP and GCP topics, with plans in 2026 to introduce additional on-the-job training and a train-the-trainer model.
- Strengthened oversight of third-party contract manufacturers, recognizing the importance of rigorous governance in a fully outsourced manufacturing model.
- Streamlined governance and reporting structures to establish clear channels for KPIs and performance metrics, providing leadership with consistent, timely visibility to support oversight and decision-making.
- Celebrated World Quality Day for a third consecutive year, engaging teams across the organization to highlight the role of quality in their work and reinforce a shared culture of excellence.

Looking ahead to 2026, the focus shifts from new program implementation to continuous improvement—optimizing and maturing the systems and processes in place.

CLINICAL TRIALS

Maintaining ethical conduct in clinical trials is a core commitment, guided and overseen by our Chief Medical Officer and Senior Vice President of Development Operations. We strive to adhere to policies aligned with international standards, including the International Council for Harmonisation (ICH), Good Clinical Practice (GCP) guidelines, and applicable regional regulations, helping to ensure trials are conducted responsibly and transparently.

Compliance with GCP and other Good Practice (GxP) standards protects participants' rights, safety and well-being while supporting the generation of reliable clinical trial data. Institutional Review Boards (IRBs) and independent Ethics Committees oversee trial ethics and are authorized to approve, require modifications to, or terminate studies at affiliated institutions. Key documents, including study protocols and informed consent forms, must undergo rigorous review by IRBs, Ethics Committees and health authorities.

Patient safety is prioritized through ongoing data review by internal monitors and specialized oversight bodies. These include Drug Safety Committees for Phase 1 studies and independent Data Monitoring Committees for larger trials, which periodically evaluate clinical data to identify potential safety concerns and recommend appropriate actions.

Patient input also plays an important role in trial design and execution. We engage patients through participation on Steering Committees for our key clinical trials and, when feasible, provide post-trial access to investigational medicines, including open-label extension (OLE) studies for Phase 3 clinical trials, to support continuity of care.

Following product launch, we plan to generate additional evidence through a coordinated, post-launch evidence strategy that includes studies using patient registry and real-world data. These efforts are designed to responsibly assess how medicines are used in routine clinical practice, deepen understanding of patient populations and inform future research while maintaining appropriate scientific and ethical oversight.

All clinical trials are required to be disclosed in publicly available databases, including **ClinicalTrials.gov**.

Applying AI thoughtfully in clinical trial operations

Artificial intelligence holds transformative potential to enhance the speed, precision and scalability of modern clinical trials. Cytokinetics is beginning to integrate AI tools into select areas of clinical trial operations to support data quality, efficiency and insight generation. These tools are designed to assist—not replace—expert judgment, and are expected to be used under defined processes and governance.

One early application supports medical coding, where large volumes of free-text clinical data, such as adverse event descriptions, must be translated into standardized medical terminology. AI tools can perform a first-pass review across tens of thousands of entries, accelerating early-stage work while maintaining human oversight for accuracy and regulatory compliance. Additional capabilities help flag data anomalies, support risk-based quality monitoring and enable medical teams to more efficiently explore patient-level characteristics.

These efforts are supported by formal oversight, including a cross-functional AI governance structure, to align responsible use with quality standards, regulatory expectations and patient safety.

"AI helps us manage scale and complexity, but people remain accountable for the science, the data and the decisions."

ERIC TERHAERDT
SENIOR VICE PRESIDENT, DEVELOPMENT OPERATIONS

Clinical Trial Participation

We believe that a participant pool that is representative of the patients we aim to serve may strengthen study results, reduce treatment bias and increase confidence that a treatment may work across different demographics. As such, we proactively seek to include patients from diverse populations across backgrounds.

Additionally, the Steering Committees of the ACACIA-HCM and MAPLE-HCM clinical trials include members from the HCM patient community, investigators and academic leaders representing a broad cross-section of knowledge and experiences.

"We strive to ensure our clinical research reflects the real-world patient populations affected by the diseases we study. We do this by strengthening access and building trust through partnerships with community organizations that understand and serve patients where they are."

KIMBERLY ERBY
DIRECTOR, CLINICAL OPERATIONS

We have partnered with the Association of Black Cardiologists on a mentorship program for emerging leaders in medicine and clinical research.

We have sponsored the Global Cardiovascular Clinical Trialists Forum's Future Trialist Fellowship and the American College of Cardiology workforce development initiative.

We have collaborated with advocacy partners on initiatives such as "ENACT: Empower, Navigate, Activate for Clinical Trials" with The Mended Hearts, Inc. and WomenHeart.

We have expanded our activities globally, to attract patients from locales including Hawaii, China, Japan, Europe, Israel and South America.

Partnership spotlight: PCNA diversity in clinical trials initiative

Cytokinetics is partnering with the Preventive Cardiovascular Nurses Association (PCNA), whose mission is to promote the role of nurses as leaders in cardiovascular disease prevention and management. Nurses play a crucial role in building trust with patients, which is vital when it comes to clinical trial participation. We provided funding and support for a member education campaign that supplied nurses with the tools needed to empower patients to make informed decisions about participating in clinical trials. The impact of this education campaign is amplified as other nurse organizations extend the reach of the educational materials through their own communication channels.

Campaign materials include a podcast miniseries and a digital patient education resource distributed to PCNA members via social media, e-newsletter, blog posts and the association website.

12,000
PCNA MEMBERS

10,000
E-NEWSLETTER SUBSCRIBERS

200
AVERAGE NUMBER OF PCNA PODCAST DOWNLOADS

PARTNERING WITH PATIENTS AND CAREGIVERS AT EVERY STEP

Cytokinetics takes a purpose-driven approach to research and development, prioritizing the needs and experiences of patients so that their voices inform our decisions.

Through a systematic approach to patient engagement and patient-guided decision making, we gain invaluable insights into what matters most to those we serve, helping us design clinical trials and develop potential therapies that address real-world challenges. As we advanced toward commercialization, we created patient support programs and educational resources that empower individuals and improve access to care. By integrating patient perspectives throughout our process, we aim to deliver innovative therapies that improve quality of life and meet the diverse needs of patients, caregivers and healthcare providers.

MATERIAL TOPICS

- Patient advocacy
- Access to effective and safe medicines
- Equity in health outcomes

125
ENGAGEMENTS WITH PATIENTS

275
HOURS OF PATIENT PARTICIPATION

KEY ACCOMPLISHMENTS

- Published Plain Language Summary of primary results from SEQUOIA-HCM to make scientific data more accessible to a lay audience
- Launched HCM Champions program to scale meaningful, compliant patient engagement
- Designed MYQORZO & You patient support program in collaboration with patient community

2026 PRIORITIES

- Continue to engage patient populations in drug development process and collaborative design of patient resources
- Increase education, awareness and patient resources by maintaining and expanding relationships with advocacy organizations
- Evaluate and refine patient support and access programs based on post-launch metrics and feedback

IN THIS SECTION

PATIENT CENTRICITY

At Cytokinetics, patient centricity is not a slogan or a side project. It's a deeply held value that shapes how we think, how we work, and how we define success. Our actions are guided by our core corporate value that Patients are our North Star.

Driven by a cross-functional Patient Centricity Council and our Senior Director of Patient Advocacy & Engagement, we prioritize putting our commitment into action through initiatives, operations and tools that enable employees to apply patient-guided decision making as appropriate to their everyday work while advancing a culture of empathy and compassion for patient and caregiver experiences. Our commitment matters more than ever as we advance activities to address hypertrophic cardiomyopathy (HCM). We recognize patients as experts and equal partners in advancing the field.

In our preclinical programs, we actively consider the genetic diversity of patients—such as investigating whether different HCM mutations influence response to therapies. We're also exploring how to meaningfully segment diverse populations to better predict which subgroups might benefit from specific interventions. Beyond the science, hearing directly from patients continues to inspire our teams; their voices provide a powerful reminder of the human impact behind the data, especially during the more challenging stretches of lab work.

During clinical research and lifecycle management, we are continuing to standardize key patient engagement points. Over the last few years, we've invested in building the infrastructure to support this evolving model. That includes the creation of systems and metrics to better quantify and track patient engagement initiatives. This allows us to anticipate regulatory and market expectations, which rightfully demand that patient engagement be a central part of the drug development process.

We are building a patient-centric foundation for commercial activities, incorporating patient input on medication design, packaging, marketing and support services. Our advocacy partnerships extend our impact, focusing on elevating patient voices, driving policy advancements and championing access to care and services.

> "Together, these strategies help ensure that patient voices influence our decisions and shape our culture. We know there's more work to do, but we believe we're building a proactive, equitable, and enduring model of patient engagement."

MARY POMERANTZ
SENIOR DIRECTOR, PATIENT ADVOCACY AND ENGAGEMENT

Published in December 2025, our latest white paper "Progress with Purpose" describes our patient centricity framework.

A Life in a Day: walking in the shoes of HCM patients

To deepen internal understanding and empathy for people living with HCM, Cytokinetics partnered with patient advisors and UK-based company A Life in a Day, to develop an immersive HCM simulation for employees. The 24-hour experience combines app-based prompts, physical kits, and live role-play interactions to simulate the day-to-day realities of living with HCM. Over a few days, Cytokinetics employees across departments and geographies choose to participate in this innovative program, engaging with realistic scenarios—doctor calls, physical limitations and emotionally charged decisions—that mirror the complexities of living with HCM. The program concludes with a moderated debrief session for the employee participants to process and share what they've learned, further deepening the newfound empathy and camaraderie from the experience. Every piece of the program was co-designed with input from HCM patient advisors to ensure authenticity and emotional depth. Forty-three employees have completed the experience with additional participation planned for 2026. The impact of the program has been immediate and powerful, inspiring new patient-centered practices across the company.

> **"It was an eye-opening exercise that has helped me gain a deeper understanding and greater empathy for patients and what we do at Cytokinetics. One of my commitments is to ensure our interviewing/recruiting practices promote HCM patients' journeys and stories."**
>
> **HR TEAM MEMBER**

PATIENT ENGAGEMENT

In 2025, Cytokinetics held over 125 patient engagements for a cumulative total of more than 275 hours. Patients are compensated for their participation in a range of activities including the following:

- Standing Patient and Caregiver Advisory Councils
- Advisory Board Meetings
- Market Research
- Video Testimonials
- Focus Groups
- Content Co-Creation
- Photo Shoots
- Content Reviews
- Social Media Features
- Speaking Events at Industry Theaters or Conferences
- General Sessions for Employee Learning
- Patient and Caregiver Speaker Panels
- Clinical Trial Steering Committees

"By collaborating with patient advisors, we gain real-time insights and feedback that inform the development of our patient marketing materials."

NASEEM EHSAN-PHAM
DIRECTOR, US PATIENT MARKETING

Patient and Caregiver Advisory Councils

Formalized, disease-specific Patient and Caregiver Advisory Councils, or PACs, have been in place at Cytokinetics since 2020. They are the backbone of our advocacy and engines of insight that shape our research, clinical programs, patient services and broader organizational awareness. We think critically about each council's composition so that the breadth of real-world perspectives are represented, and that patient input is embedded in our calendars, our budgets and our decision-making cycles. PACs meet quarterly, providing direct guidance to our teams on diverse topics from disease and patient education to navigating the healthcare system.

"I have seen how they have integrated different things we have told them in our interactions, been inquisitive on the effects of the disease, not just on our bodies, but on our minds as well as how it affects caretakers."

ERIC BROERMANN
HCM CHAMPION AND PAC COUNCIL MEMBER

HCM Champions program: deepening connection through growth

In 2025, we launched the HCM Champions program to provide a more intentional, scalable and emotionally resonant way to connect with those whose lives are impacted by HCM.

As Cytokinetics grows, so does our commitment to staying close to the community that inspires our work. The HCM Champions program invites patients and caregivers to join a vibrant network for shared stories, resources and opportunities to engage with employees and each other. Becoming an HCM Champion means being part of an ongoing conversation—and a movement—to ensure every patient feels seen, heard and valued.

Champions have the opportunity to share their stories, speak at external and internal company events, contribute to co-creation sessions, as well as make contributions on panels, through surveys and in focus groups that directly inform our thinking.

"By engaging HCM patients and caregivers with diverse experiences, we are keeping the interests and needs of the HCM community at the forefront of decision making.

ADDIE LUCAS
ASSOCIATE DIRECTOR, PATIENT ADVOCACY AND ENGAGEMENT

At a Commercial Sales training, an HCM caregiver shared her family's journey, reminding us that every strategy begins with the lived experiences of patients and caregivers.

Cytokinetics employees particpated in the American Heart Association Bay Area Heart Walk in September.

Committed to community engagement

Supporting patients extends beyond treatments and trials—it also means standing with them in their communities. Since our inception, we've deepened our commitment to community engagement through initiatives that foster visibility, connection, and solidarity. From participating in American Heart Association (AHA) and Children's Cardiomyopathy Foundation (CCF) Heart Walks to sponsoring Lou Gehrig Day in collaboration with Major League Baseball, our involvement is about more than awareness—it's about showing up in ways that matter to patients and their families. These events create space for shared experience, reduce isolation, and remind patients that they are not navigating their journeys alone.

Collaborating with patient advocates

Professional societies and community organizations play a critical role in advocating for patient access to care and serving as trusted sources for both patients and clinical care providers. We prioritize forming unique partnerships as part of a multi-pronged approach to effectively advance shared objectives.

As early as 2015, Cytokinetics developed relationships with European advocacy organizations and later included individuals to represent European perspectives on the HCM Patient and Caregiver Advisory Council (HCM-PAC). That early work with the patient community set the stage for where we are today—with a growing number of feet on the ground across the European patient community.

> "In all our interactions, every member of the Cytokinetics team has shown an unwavering commitment to the interests of patients and to hearing their voices, regardless of background or geographic location."

EMIL TSENOV
CEO OF THE EU-BASED HCM PATIENT FOUNDATION
EARLY MEMBER OF THE CYTOKINETICS HCM-PAC

The Cytokinetics Communications Grant Program: amplifying advocacy resources

For the past seven years, the Cytokinetics Communications Grant Program has supported patient advocacy organizations to help expand their reach, awareness and community engagement by providing resources for new or crucial communications, marketing or outreach initiatives that would otherwise be challenging to implement. Cytokinetics has no oversight, involvement or management of the actual projects, programs or outputs. The goal of the Communications Grant Program is to assist patient advocacy organizations by increasing resources in order to better support patient communities and bring increased disease awareness in the communities they serve.

The recipients of the 2025 Cytokinetics Communications Grants were:

- AICARM APS (Italian Association of Cardiomyopathies)
- HeartBrothers Foundation
- HeartCharged Corporation
- Hypertrophic Cardiomyopathy Association
- Stichting Cardiomyopathie Onderzoek Nederland (Foundation Cardiomyopathy Research the Netherlands)

> "These grants play a pivotal role in advancing initiatives to increase cardiovascular diagnosis, expand patient and family education, and strengthen comprehensive support to improve overall well-being."

ANDREA MINADAKIS
ASSOCIATE DIRECTOR, GRANTS AND ADVOCACY OPERATIONS

PATIENT EDUCATION AND SUPPORT

Access to medicine

Cytokinetics aspires to provide equitable access for all patients. As such, we are developing programs for patients and healthcare providers in order to remove barriers, so our products are accessible and affordable to those in need. They include:

- **Access and Affordability** — Support to help understand and navigate insurance coverage and financial assistance options for eligible patients
- **Education** — Patient and healthcare provider education and resources to help navigate the patient's treatment journey
- **Behavioral and Wellness** — Tools and resources to support patient engagement and help manage adherence to treatment

Plain language summaries

Plain language summaries translate complex clinical research into clear, non-technical, accessible information for study participants, patients, caregivers and the broader public. In May 2025, Cytokinetics published a plain language summary of SEQUOIA-HCM, the Phase 3 clinical trial of *aficamten*, explaining the trial design and outcomes. The summary supports patient understanding and health literacy, builds trust through transparency, and reflects Cytokinetics' commitment to inclusive, responsible communication and patient engagement.

Designing Patient Support Programs

The Patient Services and REMS team is a cross-functional group that developed and leads the governance of the company's patient and provider Risk Evaluation and Mitigation Strategy (REMS) and Patient Support Programs (PSPs). The team oversees business rules, operational processes and supporting systems that enable compliant, streamlined, and patient centered education and support. Their design approach focused on creating programs that are intuitive, responsive and reflective of real-world patient and provider needs.

Understanding lived experience

Effective design begins with understanding the lived experience of patients and providers—and building around reduced friction, improved access and safe, appropriate use. Every touchpoint is intentionally designed, with the aspiration of simplified processes and clear communications. Listening is foundational. Insights from advocacy groups, market research and advisory boards reveal real-world pain points that informed program design—from communication style to educational materials. Patients want clear, timely information without overload. Providers want support that fits into existing workflows. The team aspires to meet both where they are and ensure the program is practical in everyday care.

Flexibility and access

Flexibility is essential because no two practices—or patients—are the same. Adaptability will be built directly into the model so providers can engage in the way that works best for them, whether through one of our selected specialty pharmacy relationships, or their own internal pharmacy. The goal is to integrate into existing workflows, not force new ones. By offering multiple access points and honoring the diversity of practice operations, the program intends to truly support providers while meeting patients where they are. Our vision and focus will be on operational excellence and continuous improvement. In the early post-launch phase, we plan to closely monitor patient and provider feedback, time-to-therapy metrics, and overall program performance during a structured "hypercare" period, making adjustments wherever needed. The attention paid to these critical details will create meaningful moments of support and are intended to set Cytokinetics apart from other programs in the industry.

MYQORZO & You™: personalized patient support

MYQORZO & You™ is a comprehensive patient support program designed to help individuals feel informed, supported and confident as they start and continue treatment with MYQORZO. The program offers assistance at every step of the journey, beginning with guidance on what to expect before starting treatment and how dosing and monitoring work over time. Patients are connected with a MYQORZO Navigator who can answer questions, explain program requirements and help coordinate next steps. Educational materials support understanding of treatment, safety monitoring and ongoing care, while specialty pharmacy coordination helps streamline home delivery. MYQORZO & You™ also provides support with insurance benefits investigation and financial assistance for eligible patients.

MYQORZO is available through a restricted distribution program called the MYQORZO Risk Evaluation and Mitigation Strategy (REMS) program to help monitor and minimize risk of heart failure. Patients must enroll in the REMS program before starting treatment, and prescribers and pharmacies must also be certified. As part of the REMS, patients receive education on safe use and return for echocardiograms as directed by their healthcare provider. Together, MYQORZO & You™ and the REMS Program reflect Cytokinetics' commitment to thoughtful, personalized support and patient safety throughout the treatment journey.

MYQORZO & You™ PERSONALIZED PATIENT SUPPORT

PATIENT ACTIVATION AND ENGAGEMENT

Access and Reimbursement	Support investigating patient's health insurance benefits, out-of-pocket cost, prior authorization and/or appeal criteria and submission
Free Trial Program	Free drug supply during trial period for eligible government-insured patients *Limited to one use per patient per lifetime.* *On-label use only. Age and residency criteria apply.*
Bridge Program	Free drug supply for up to 12 months for commercially insured patients due to coverage delay

PATIENT AFFORDABILITY

Co-Pay Program	Financial assistance for commercially-insured patients to reduce out-of-pocket costs for MYQORZO and echocardiograms
Patient Assistance Program	Free supply of MYQORZO for eligible patients meeting financial criteria

HCM Beyond the Heart

Launched in 2024, *HCM Beyond the Heart* is a distinctive market development campaign that brings visibility to the full impact of hypertrophic cardiomyopathy beyond its clinical presentation. The campaign underscores the complex, multidimensional realities of living with HCM—spanning physical, emotional and social dimensions—while promoting a comprehensive approach to care that recognizes the whole person.

Through compelling storytelling across multiple media channels, the campaign features real individuals living with HCM,* sharing authentic experiences that reflect both the challenges and resilience within the community. By elevating these voices, *HCM Beyond the Heart* reinforces the importance of care that acknowledges patients' lived experiences and supports their ability to define and pursue life on their own terms.

The campaign has been rolled out via a digital ecosystem that includes a website, advertisements in journals and association publications and social media.

* Actual consented patients





HCMBeyondtheHeart.com

CULTIVATING INCLUSION, INTEGRITY AND EXCELLENCE

Culture shapes how we work together, grow as a company and deliver for patients. We focus on attracting, developing and retaining a diverse community of qualified colleagues motivated by our mission to improve lives.

Cytokinetics has built an award-winning reputation as a great place to work, supported by a strong culture of inclusion. In our 2025 Employee Engagement Survey, we achieved an engagement score of 8.1, placing the company in the top quartile of our industry. This positive workplace environment has also contributed to a relatively low attrition rate of 10% in 2025, compared to the U.S. biopharmaceutical industry average at the 50th percentile of 14.5%, based on AON data. New initiatives to strengthen our global team include a structured mentorship program, leadership development workshops and a clear, consistent decision-making framework that reinforces accountability and action.

MATERIAL TOPICS

- Representation, empowerment, mutual respect
- Human capital management

8.1
EMPLOYEE ENGAGEMENT SCORE

94%
PARTICIPATION IN EMPLOYEE SURVEY

KEY ACCOMPLISHMENTS

- Onboarded Cardiovascular Account Specialists with emphasis on shared culture and values
- Established programs for mentorship, transformational leadership and change management training
- Hired head of HR for Europe and extended EH&S oversight to European offices

2026 PRIORITIES

- Build a future-ready leadership bench through talent development and mentorship
- Prioritize organizational excellence including rollout of DARE decision-making framework
- Listen to and engage employees to strengthen company culture as we grow and expand
- Continue global integration of employee experience with new country culture leads

IN THIS SECTION

GROWTH AND GLOBAL EXPANSION

As Cytokinetics grows globally, we are focused on scaling our organization in ways that preserve our culture, strengthen collaboration and support consistent execution across functions and geographies. Culture remains a critical foundation for performance, alignment and long-term success.

As Cytokinetics transitions from a late-stage, pre-commercial organization to a fully integrated biopharma company, we are navigating significant organizational change. This evolution includes new leadership layers, expanded commercial capabilities and incentive and performance structures that differ across functions. Managing this complexity thoughtfully is essential to maintaining alignment, collaboration and a shared sense of purpose as the company grows.

Rapid expansion has also changed the composition of our workforce. Significant hiring to support global operations, combined with natural turnover among longer-tenured employees, has reduced average tenure and increased the importance of intentional knowledge sharing and cultural continuity. Engagement trends vary across locations, with some offices experiencing signs of organizational fatigue, reinforcing the need for local connection, leadership visibility and responsive engagement efforts.

In response, Cytokinetics is reinforcing leadership accountability for culture while strengthening mechanisms that support cohesion across teams and geographies. This includes targeted engagement initiatives, site-specific listening efforts, clearer alignment of goals across functions and consistent communication of values and expectations. By embedding our cultural strengths into leadership behaviors, talent development and global operating practices, we aim to preserve what defines Cytokinetics while enabling sustainable growth and execution at scale.

> As we scale, the priority is maintaining momentum while ensuring the right people and capabilities are in place—so growth strengthens, rather than dilutes, the culture and values that define Cytokinetics."

YULYMAE DINAPOLI
SENIOR VICE PRESIDENT, HUMAN RESOURCES

We > Me

As one of Cytokinetics' core values, We > Me reflects our belief that diverse perspectives, backgrounds and experiences strengthen our work and our impact. We strive to create an environment where every employee feels valued, respected and supported in bringing their authentic self to work. Inclusion is essential to collaboration, innovation and collective success.

Our aspiration is to build a workforce that reflects the diversity of the patients and communities we aim to serve. We take an intentional approach to recruitment and talent development. To support inclusive hiring practices, we focus on expanding access, reducing bias and reinforcing fairness throughout the recruitment process. Key efforts include:

- Establishing partnerships and outreach initiatives with universities and organizations focused on expanding access to qualified candidates from underrepresented groups
- Increasing engagement with educational institutions to connect with diverse students and early-career talent interested in opportunities at Cytokinetics
- Providing interviewer training focused on fair, merit-based and consistent candidate evaluation

Beyond recruitment, we support a merit-based approach to growth and advancement, providing employees with opportunities to develop and progress based on their performance and contributions.

Building a new commercial team

In 2025, Cytokinetics welcomed its first-ever commercial sales team with the hiring of Cardiovascular Account Specialists (CAS)—a milestone aligned with the launch of MYQORZO™ (*aficamten*). Drawn from a highly competitive recruiting process, the CAS team brings deep cardiovascular and rare disease experience while embodying the company's mission, values and patient-first mindset.

Onboarding, conducted in two waves beginning in August and October, emphasized both preparation and belonging, combining comprehensive training in hypertrophic cardiomyopathy, market development and compliance with immersion in Cytokinetics' culture and policies. As trusted partners to healthcare professionals, CAS team members play a critical role in advancing disease awareness, supporting new patient starts and building strong, collaborative relationships.

CAS TEAM EXPERIENCE

21 YEARS AVERAGE INDUSTRY EXPERIENCE

14 YEARS AVERAGE CARDIOVASCULAR EXPERIENCE

4 YEARS AVERAGE RARE DISEASE EXPERIENCE

> "I knew what I needed to do before my first day as a new hire and what to expect my first week with the organization."
>
> **CAS TEAM MEMBER**

> "Cytokinetics' onboarding process was a well-oiled machine and reaffirmed I made the right decision to join."
>
> **CAS TEAM MEMBER**

Cardiovascular Account Specialists gather in South San Francisco.

Human Capital Management and Development

Our talent management strategy and development initiatives are designed to strengthen our leadership bench and pipeline, foster a culture of continuous learning and innovation, build key organizational capabilities to enable our growth and to enhance and optimize employees' experience and effectiveness within the company.

Performance management: supporting employee development

As part of our formal performance review process, we employ a performance management cycle, which guides an employee through goal setting, a mid-year check-in and a year-end performance review. The annual performance management cycle enables managers to communicate expectations, evaluate progress and provide actionable and meaningful feedback. An overhauled review format was launched ahead of the 2024 year-end review cycle to better support clarity, accountability and employee development. The redesigned approach simplified the prior 120-point rating system into four defined performance categories and introduced consistent definitions for evaluating both what employees achieve and how they demonstrate the company's core values. The process also has been further enabled by senior level leaders as well as people manager live alignment sessions prior to launch. The updated process emphasizes meaningful performance conversations over rating debates and incorporates a "feed-forward" approach to encourage continuous improvement while maintaining a supportive culture.

In 2025, the new framework was fully implemented across the organization with ~100% of employees completing reviews. Post-review survey results indicate strong employee and manager response to the updated process. A majority of respondents reported clarity around performance expectations and priorities, with approximately 92% agreeing or strongly agreeing that they understood how their performance contributed to team and functional goals. Employees also reported high levels of confidence in manager feedback, with more than 90% indicating they received actionable guidance to apply moving forward. Overall, the year-end performance review process was viewed as valuable by most participants, reflecting the effectiveness of the simplified, conversation-driven approach.

In addition to the annual performance management cycle, we offer career workshops and toolkits such as Individual Development Plans (IDPs) as resources to support our employees' growth at Cytokinetics. IDPs prompt employees to reflect on our business priorities, their performance goals, as well as their career aspirations, and identify ways to further leverage their strengths, crystallize development focus and craft specific developmental actions to achieve their goals.

Thrive talent development hub

Cytokinetics' talent and learning development hub, *Thrive*, guides individuals to achieve their professional development goals. The curriculum offered via *Thrive* reflects our commitment to nurture our employees' ongoing growth at Cytokinetics and reinforces our culture of inclusion and belonging. In addition to onboarding materials, policies and compliance training, the following learning and development programs are available via *Thrive*:

- Navigating Change
- Foster a Culture of Inclusion and Belonging
- Giving and Receiving Feedback
- Your Career
- Career Conversations (for People Managers)

Recent additions focus on supporting and elevating our people leaders, with a new course offering: Leading Change for People Leaders, and the establishment of a people leader forum and leadership newsletter. Additionally, training offerings have been adjusted to shift from concepts learning to skill adoption and application. Sessions are designed with less "teaching" and much more real business scenario discussions and applications, aiming to close the "say" vs. "do" gap.

Employee engagement

Cytokinetics uses regular employee engagement surveys as a way to listen to employees and better understand their experiences at work. The most recent survey was conducted over a period of two weeks in September 2025 using the Peakon platform, with 94% participation, reflecting strong employee engagement in sharing feedback. The survey included 38 questions across four focus areas: Engagement, Diversity and Inclusion, Health and Wellbeing, and Transformation and Change.

Results reflected high levels of employee satisfaction, with overall satisfaction rated 8.1 out of 10 and employees reporting strong alignment with team goals (9.1), supportive relationships (8.5), and open manager communication (8.8). Beginning in 2026, the survey cadence will shift from annual to biannual, complemented by targeted pulse surveys, enabling ongoing dialogue and timely follow-up informed by employee input.

Cyto Exchange: mentorship program

Cyto Exchange is a newly launched, company-wide mentorship program designed to strengthen cross-functional connections, support leadership development and deepen interpersonal relationships and ties across region/function/level. Open to all employees, the program provides a structured yet flexible platform for mentorship that blends preparation, resources and relationship-building.

In its inaugural six-month cycle, 124 employees participated, forming 66 mentor–mentee pairs, including 16 members of the Senior Leadership Team serving as mentors. Early feedback has been strong, with participants reporting high satisfaction and mentor quality scores well above external benchmarks. Employees highlighted the program's thoughtful structure, practical resources and ability to create authentic, meaningful connections across roles and functions.

66
MENTOR–MENTEE PAIRS

16
MEMBERS OF THE SENIOR LEADERSHIP TEAM SERVING AS MENTORS

4.8/5
AVERAGE POST-MEETING SATISFACTION

"This program exceeded my expectations. I have always been a fan of informal mentoring, but the way in which Cytokinetics is doing this blends structure and preparation to create an environment for an authentic relationship to grow between mentor and mentee. Best I have seen in 28 years in the Pharma Industry."

PARTICIPANT MENTOR

DARE decision-making framework

DARE is Cytokinetics' enterprise-wide decision-making framework, initiated in Summer in 2025, and piloted with a key strategic business decision with 22 cross functional leaders in Q4. The DARE framework and process supports clear, consistent and accountable decisions across the organization. Standing for Define, Analyze, Recommend, Execute, DARE provides a shared structure for identifying opportunities, evaluating options, assessing risk and translating decisions into action.

The framework clarifies roles within the decision-making process—such as decision maker, driver, advisors and stakeholders—helping teams stay aligned and move efficiently from discussion to execution. By encouraging collaboration, transparency, and thoughtful risk assessment, DARE is intended to strengthen how decisions are made at every level of the company. As it is applied consistently across functions and locations in 2026, the framework will reinforce a common decision-making standard and supports a culture of accountability, focus, and impact—aligning teams around decisions that advance Cytokinetics' mission and long-term success.

"I applaud Cytokinetics for bravely holding up the mirror and saying, 'Let's do this better.' We heard employees say they want more empowerment and autonomy, and we're acting on that."

SELENA YUAN
HEAD OF TALENT MANAGEMENT

Transformational Leadership Program

In 2025, Cytokinetics launched its first high-potential development initiative: the Transformational Leadership Program, a strategic investment in building enterprise leadership capability across functions. Designed and led by the Talent Development team, the program supports Associate Director through Senior Director–level leaders identified through formal talent reviews and manager nomination.

The six-month program combines three full-day, in-person sessions focused on Leading Self, Leading People and Teams, and Leading the Business with six virtual experiences, including senior leader Q&A sessions ("Leadership Unplugged") and peer coaching circles. Participants also collaborate on small-group capstone projects that apply learning to enterprise priorities. Capstone projects were carefully selected, strategic, enterprise-wide initiatives which serve as a business enablers. In 2025 the capstone projects were: artificial intelligence, data management, global ways of working, and advanced rotation programs.

The curriculum blends Cytokinetics' internal leadership experience with external expertise in advanced leadership development. Early feedback from Cohort 1 demonstrates strong impact and engagement, reinforcing plans to launch a second cohort in 2026, incorporating refinements based on participant and manager feedback.



> Having the opportunity to present to Senior Leaders through the capstone project was a very valuable experience and really one of the key benefits I took away from this program, in addition to the network building and the amazing tools/frameworks/activities. I feel I am better equipped to be successful as a leader at Cytokinetics, as well as to model leadership best practices and to be a resource in this regard for others.
>
> **PROGRAM PARTICIPANT**

> The Transformational Leadership Program strengthened my ability to lead through change while deepening my understanding of how to lead myself, my teams, and the business in support of Vision 2030. Just as importantly, it allowed me to build a strong, lasting network of peer leaders whose collaboration and shared commitment will be invaluable as we continue to grow the company together.
>
> **PROGRAM PARTICIPANT**

Leadership development workshops

Cytokinetics offers leadership development workshops to support people leaders across the organization with the skills needed to lead effectively in a growing, evolving company. All people leaders with at least one full-time direct report are invited to participate, spanning all functions and levels of leadership. The workshops are delivered both in person and virtually and will continue as a core element of leadership development.

The curriculum focuses on essential leadership capabilities, including leading change, behavior-based feedback, and development and career conversations. Workshops use consistent materials—such as slide decks, tip sheets, and participant guides—to create a shared leadership framework, while allowing for customization when delivered to intact or functional teams.

These targeted workshops create a common operating system for how management works at Cytokinetics, to provide consistent employee experiences and accelerate typical learning curves. We are consciously building and expanding learning agility, change management, and team engagement skills to prepare our people leaders are prepared to lead their teams into the future and align with current and future company vision.

2025 TRAINING HIGHLIGHTS

139 PARTICIPANTS IN 11 LEADING CHANGE SESSIONS FOR PEOPLE MANAGERS

188 PARTICIPANTS IN 14 INCLUSION AND BELONGING TRAINING SESSIONS

325 PARTICIPANTS IN 12 GIVING AND RECEIVING FEEDBACK SESSIONS

Postdoctoral Fellows Program

The Postdoctoral Fellows Program provides a unique training opportunity for the next generation of scientists preparing to enter the biotech and academic research communities while supporting the discovery of potential new medicines for cardiovascular and neuromuscular diseases. Fellows lead independent research projects focused on key aspects of muscle biology, including muscle contractility, mitochondrial function and muscle metabolism. Guided by Cytokinetics scientists, they collaborate across the company and participate in enrichment opportunities in communication, leadership and lab management.

Established in 2023 as a two-year program, in 2025 we extended the potential tenure to up to 4 years, allowing a longer runway for publishing and research. This fully funded program offers competitive salaries, with standard incremental tiered pay increases year over year, benefits and travel funding for research conferences. The program sponsored two fellows in its inaugural year, with new fellows recruited as positions become available.

"The Postdoc Program at Cytokinetics has offered me an intellectual environment where I can learn about the industry and therapeutic development during a very exciting time of growth for the company, while also offering mentorship and access to science and materials that have the opportunity to really push my research forward."

BEE PRUZINSKY
POSTDOC FELLOW

Internship Program: boosting young professionals

Through our annual paid internship program, we aim to provide a challenging and rewarding experience to help build a strong foundation for a career in the biopharmaceutical industry. We believe that investing in enthusiastic undergraduate and graduate students and recent graduates brings fresh perspectives and insights to our teams.

Interns gain knowledge of different stages of drug discovery, development and commercialization; complete a group project to develop skills such as stakeholder interviewing, public speaking and collaboration; and participate in a lunch forum with the CEO, off-site events, team building activities.

22
INTERNS IN 2025

10
FORMER INTERNS HIRED AS EMPLOYEES SINCE PROGRAM INCEPTION

Intern activities include a day volunteering with students in a science classroom.

"The internship experience and program here is robust. It's intentional with not only the projects that we're doing or assigned, but the different types of programming."

RAYMOND RUIZ
INTERN, CLINICAL OPERATIONS

"I am a biomedical engineering student, so hands-on engineering is something that was interesting to me. I had the opportunity to see how my degree can be applied in the real world."

MERYL SAMPSON
INTERN, CLINICAL BIOMETRICS

Hear from our 2025 Interns in a series of videos on **Networking & Mentorship**, **Learning & Growth**, and **Culture** shared on the **Cytokinetics YouTube channel**.

Wellness and Benefits Program

We offer competitive compensation and robust benefits tailored to the unique needs of employees and their families. Available to employees working at least 24 hours per week, most benefits begin on the date of hire and include: medical, dental and vision plans; Health Savings Account (HSA) contributions or Flexible Spending Account (FSA); life insurance and disability; 401(k) retirement savings plan; employee stock purchase plan; paid time off including 8 weeks of paid parental leave and up to 12 weeks of paid medical leave; and optional legal and identity theft protection and pet insurance. Wellness perks include an onsite fitness center, annual flu shots, biometric screenings, personal financial coaching and more. Details on our full list of benefits and wellness offerings are available at Careers on our website at **www.cytokinetics.com**.

Augmented Pay
Employees are eligible to receive the equivalent of 100% of their pay during disability, parental, or family medical leave. This benefit is integrated with state-provided benefits and covers up to 12 weeks for disability or 8 weeks for parental or family leave within a rolling 12-month period.

Adoption Assistance
Cytokinetics supports employees in building their families by offering up to $5,000 in reimbursement for eligible adoption expenses. These may include agency fees, court costs, legal fees, foreign adoption fees and medical expenses.

Wellness Reimbursement
Employees can receive reimbursements for eligible well-being-related expenses, with an annual benefit of $300. These include products or services such as fitness app subscriptions, smartwatches, fitness classes, gym memberships, sports gear, massage services and more.

Employee Assistance Program
This program offers 24/7 confidential support for employees with five free consultations per calendar year. Services include childcare and eldercare assistance, daily living services, financial services, identity theft recovery, legal services and LGBTQ+ resources.

Pay equity

Cytokinetics proactively manages pay equity through merit-based annual compensation reviews and salary range updates informed by market data. Each year, we review salary ranges and evaluate employee compensation by gender, level and tenure, identifying any discrepancies based on grade penetration threshold. To minimize bias, new hire offers and promotions are reviewed in an assessment format that considers only the role and experience level. Short-term actions may include immediate adjustments for identified disparities after annual reviews.

Education assistance

Cytokinetics supports employees pursuing further education and career advancement by offering up to $10,000 annually in tuition reimbursement for degrees or certifications directly related to our business.

Workplace recognitions

Cytokinetics was recertified as a Great Place to Work in 2025. We have also been cited by Fortune magazine as a “Best Workplace in BioPharma” and “Best Workplace in the Bay Area” for the past four consecutive years, and by the San Francisco Business Times as a “Best Place to Work in the Bay Area” for the past five years since 2021.

Great Place To Work. Certified FEB 2025-FEB 2026 USA

SAN FRANCISCO BUSINESS TIMES & SILICON VALLEY BUSINESS JOURNAL
BPtW
2025 BEST PLACES TO WORK

FORTUNE BEST WORKPLACES IN THE BAY AREA™ 2025

FORTUNE BEST WORKPLACES IN BIOPHARMA™ 2025

Strength in Inclusion

Cytokinetics fosters an inclusive culture in which diverse backgrounds are recognized and valued. In the latest employee engagement survey, our diversity and inclusion score was 8.8, which is in the top 10% of companies in the healthcare pharmaceuticals, biotechnology and the life sciences industry.

Celebrating and learning together

Throughout the year, employees are invited to participate in special events that celebrate diversity and inclusion. These events create opportunities for connection, learning and cultural exchange—through history and trivia, performances and traditional food—while building awareness and understanding of diverse cultural observances.

Employees at Diwali event in South San Francisco office

Employee Resource Groups

Employee Resource Groups (ERGs) play an important role in cultivating a culture of belonging at Cytokinetics. These voluntary, employee-led communities are open to all and provide space for connection, learning and mutual support that extends beyond day-to-day work.

Cytokinetics EmpowHERment Network: succeeding together

Founded in 2022, the Cytokinetics EmpowHERment Network provides a forum for women across the organization to connect and, share experiences. Over time, the group has focused on building a strong foundation—maintaining visibility, listening to members and providing a trusted resource.

In 2025, EmpowHERment continued to prioritize meaningful conversations and community-building while balancing the demands of a critical year for the business. Activities included planning educational sessions open to all employees and supporting conversations around women's health topics. The group regularly surveys participants to better understand evolving needs and shape future programming.

Looking ahead, EmpowHERment aims to bring women together across functions and geographies, offering an informal, supportive touchpoint.

> "Meeting the moment is making sure that we are continuing the conversations. As we are expanding into different countries, it's an opportunity to gain even more perspectives."

ROSE ANN PANUNCIO-AU
ASSOCIATE DIRECTOR, HUMAN RESOURCES

CytoPride: authenticity at work

CytoPride supports an accepting and affirming workplace for LGBTQIA+ employees and allies, emphasizing connection, authenticity, and community. In a year when organizational focus was squarely on preparing for commercialization, the group prioritized creating safe spaces for employees to connect, share experiences, and support one another.

In 2025, CytoPride hosted a robust Pride Month program that included educational newsletter features, inclusive discussions, and a facilitated trivia event led by an external expert. The group intentionally highlighted both celebratory and lesser-known aspects of LGBTQIA+ history, reinforcing the importance of honest education and dialogue. CytoPride also contributed to company-wide moments of engagement, including Science Is in Our Soul Day.

As the company looks to 2026, CytoPride plans to expand education throughout the year, strengthen community connections, and continue serving as a source of support and resilience for employees.

> "CytoPride allows us to come together to share experiences, listen and help each other be resilient as a community."

ROY EIKLEBERRY, CPM
HR EXECUTIVE ASSISTANT AND PROGRAM COORDINATOR

ACTING WITH INTEGRITY AND PURPOSE



Cytokinetics strives to operate in accordance with ethical and professional principles across our operations, encompassing interactions with colleagues, patients and caregivers, scientific and clinical partners, service providers, investors and governmental bodies, both locally and globally.

We embed compliance into onboarding, role-specific training, and guidance for everyday decision-making. Systems for data privacy, cyber security and AI governance are designed to protect personally-identifiable and sensitive information as our operations, technologies and geographic footprint expand. Together, these integrated frameworks promote accountability, help manage risk and enable responsible growth while maintaining transparency, regulatory alignment and trust.

MATERIAL TOPICS

- Corporate governance
- Ethics, quality and compliance
- Data security and privacy

~100%
EMPLOYEES COMPLETING CODE OF ETHICS TRAINING

0
MATERIAL DATA BREACHES

KEY ACCOMPLISHMENTS

- Prepared for launch of MYQORZO™ in compliance with regulatory requirements
- Completed annual training for ~100% of employees on Code of Ethics and Business Conduct including new and updated policies
- Enacted AI Governance program to support leadership in responsible evaluation and adoption of specialized AI tools

2026 PRIORITIES

- Continue evolving compliance, data privacy and information security policies, practices and systems as operations expand globally
- Continue supporting teams in evaluating responsible implementation of AI tools across business functions

IN THIS SECTION

GOVERNANCE, ETHICS AND COMPLIANCE

Code of Ethics and Business Conduct

Our Code of Ethics and Business Conduct serves as a guiding framework for consistent alignment with ethical and professional norms. Each year, we review the Code to confirm that it remains relevant as Cytokinetics grows and evolves.

"We have established a first-in-class onboarding for our new sales colleagues with a core curriculum that embeds our code of conduct and compliance training, building a circle of trust as we begin this journey together."

KARI K. LOESER, J.D.
VICE PRESIDENT, CHIEF COMPLIANCE OFFICER

The purpose of our Code of Ethics and Business Conduct is to provide a written framework for our company's commitment to compliance and to:

- Encourage integrity and ethical behavior, including the proper management of conflicts of interest in both personal and professional contexts
- Express our dedication to delivering complete, unbiased, accurate, prompt and clear disclosures in filings with regulatory bodies and other public communications
- Promote awareness and compliance with relevant governmental laws, regulations, industry standards, and rules
- Specify processes to support accountability and encourage the immediate internal reporting of any breaches of the Code to designated company authorities
- Ensure comprehension of our policies, outline individual responsibilities and guarantee prompt notification of any Code infringements to the appropriate company authorities
- Incorporate standards that all directors, officers and employees are expected to follow and support



Corporate governance: accountability in action

Integrity starts at the top with our Board of Directors, which is committed to effective corporate governance. Board diversity and Board independence are important to the composition of the board which currently includes 30% women and 90% independent directors.

More information on corporate governance, including Board Committee charters, governance documents and our Code of Ethics, is available at **https://ir.cytokinetics.com/corporate-governance/highlights**

Compliance training

We reinforce compliance with our Code of Ethics and Business Conduct through regular employee training. On an annual basis, all employees are expected to be trained on our Code, either upon being hired or yearly on their anniversary. These training sessions are updated annually by our Chief Compliance Officer. In 2025, ~100% of our employees completed Code of Ethics and Business Conduct training.

In addition, all employees must acknowledge our anti-harassment and anti-discrimination policy, which is part of the Code, and complete the company-offered training on these topics within the first several months of employment.





The "Compliance Corner" repository within *Thrive,* our internal training system, houses general and role-specific training modules, compliance resources, and training acknowledgment forms.

Ethics and compliance hotline

Our Code addresses processes for reporting ethics concerns confidentially at Cytokinetics for all stakeholders. In keeping with our culture of transparency, we believe in clear and open conversation. We want employees to feel comfortable talking to their supervisors or other managers if they think something does not measure up to our policies or standards. We openly encourage and support the mantra "If in doubt, please reach out."

Employees can also surface concerns or questions directly to our Compliance Department, whether by email, phone or in person, or to our anonymous and confidential Ethics and Compliance Hotline. Administered by a third party, the Ethics Hotline is publicly available 24/7 and can be accessed by phone or online to report concerns. All reports to the Ethics Hotline are required to be investigated thoroughly. We have a strict policy against retaliation for reports made to managers, to Compliance or through our Ethics Hotline.

Alignment to PhRMA Code: ethical engagement with healthcare professionals

Adherence to ethical standards encompasses both our rigorous internal code and the guidelines set by the Pharmaceutical Research and Manufacturers of America (PhRMA) Code for industry engagement with healthcare professionals. This Code embodies the fundamental principle that healthcare professionals should make decisions based solely on medical needs and their expertise, ensuring that patient care remains the top priority.

The PhRMA Code is a voluntary framework designed to govern interactions between pharmaceutical companies and healthcare professionals. It promotes ethical practices by prioritizing patient outcomes, advancing medical knowledge and maintaining trust in the healthcare community.

Key principles include focusing interactions on education to enhance understanding of treatments, prohibiting non-educational gift items of value to avoid the perception of undue influence and providing occasional, modest meals only in educational settings. Consulting and speaker engagements must involve fair compensation, and companies must transparently disclose payments under federal laws like the Sunshine Act. Alignment with the PhRMA Code underscores our dedication to ethical business conduct, maintaining transparency, collaboration and trust in our interactions with healthcare professionals, and is also part of our legal obligation for U.S. states that have adopted the PhRMA Code as law.

Data Privacy and Cyber Security

Our Privacy and Cyber Security programs safeguard clinical, commercial, employee and company data by implementing policies and procedures that guide privacy, security and data protection decisions.

As we grow, we continue to raise awareness among employees and contractors about their roles in protecting the organization, safeguarding sensitive or personally-identifiable information, and incorporating Privacy by Design—all while improving our early detection systems to mitigate threats. With operations expanding into Europe and other global regions, we are building data systems which are adaptable to a variety of regulatory environments. External collaborators must meet technical security requirements which are critical to proactively managing third-party risk. We experienced no material data breaches in 2025.

Our Privacy Program is overseen by the Vice President, Chief Compliance Officer and the Privacy Council to review the programs' ongoing performance and take action accordingly. Our **Privacy Policy** describes the principles for collecting and processing personal data when conducting our business. It aligns with the basics of relevant privacy laws, including the U.S. Health Insurance Portability and Accountability Act (HIPAA) and applicable state privacy laws. We do not sell or share personal data for marketing purposes.

We engage employees through periodic training and education initiatives including Cyber Security Awareness Month, seminars, lunch-and-learn events and cyber security content on our company intranet.

Our Cyber Security Program is headed by the Vice President, Information Technology & Chief Information Security Officer (CISO) and utilizes the Cyber Security Advisory Board to assess the program's ongoing performance and implement necessary actions. Our Cyber Security Program is informed by the National Institute of Standards and Technology Cybersecurity Framework (NIST CSF) and utilizes the principles, processes, practices and controls recommended to help protect our systems and data including all types of user-awareness activities (e.g., sponsored phishing, education initiatives, seminars, etc.).

AI governance program

Cytokinetics manages the acceptable use and responsible adoption of artificial intelligence (AI) tools through a thoughtful governance program developed in partnership with senior leadership. Introduced in 2024 and put into practice throughout 2025, the process includes educating leaders on AI risks and using a structured, question-based assessment to evaluate intellectual property (IP) considerations, training, data integrity, privacy, and business impact. Reviews by functional heads drive coordinated decision-making and implementation. This framework has guided the company toward deploying appropriate systems that address specific scientific, clinical, commercial, legal, or general operational needs, enhancing efficiency while remaining aligned with established legal, privacy, and cybersecurity practices.

> "Continued commercialization expands our security landscape—new systems, vendors, geographies and distributed teams. Our work focuses on enabling and safeguarding a more complex operation and a brand with rising visibility in the market."

ERIC BROWN
VICE PRESIDENT, INFORMATION TECHNOLOGY AND CHIEF INFORMATION SECURITY OFFICER (CISO)

Humane Treatment of Animals

In the development of new medicines, regulatory agencies rely on animal data to evaluate the safety and efficacy of new drug candidates. We acknowledge this necessity and are committed to the ethical, moral and scientific responsibility of ensuring the welfare of these animals.

Cytokinetics is licensed by the State of California Department of Public Health to keep and use laboratory animals. Our care for research animals is designed to adhere to the standards set by U.S. National Institutes of Health's Guide for the Care and Use of Laboratory Animals. We strive to not only meet, but to surpass all relevant standards for animal care and welfare. We follow the principles of Reduction, Refinement and Replacement (the 3 Rs). Our research activities are overseen by a duly established Institutional Animal Care and Use Committee (IACUC). The IACUC reviews all animal use protocols, oversees compliance with applicable regulations, inspects animal facilities and manages training and educational programs, as well as animal handling.

SUPPORTING COMMUNITIES THROUGH PARTNERSHIP AND IMPACT

We believe meaningful impact grows through collaboration, connecting with others, learning together and working toward shared goals.

Cytokinetics brings this belief to life by engaging with local communities and causes across the regions where we operate. In 2025, the company contributed more than $2.7 million in corporate grants and sponsorships, including charitable donations through our corporate giving program. These efforts support research and education initiatives, patient community events and campaigns that raise awareness for diseases aligned with our research.

MATERIAL TOPICS

Community engagement

500+
EMPLOYEE VOLUNTEER HOURS

19
GIVING PROGRAM RECIPIENTS

KEY ACCOMPLISHMENTS

- Completed second year of Corporate Giving Program, supporting 19 nonprofit organizations focused on science education, access to healthcare for cardiovascular disease and local at-risk communities
- Supported employees in volunteering more than 500 hours

2026 PRIORITIES

- Continue to evaluate ways to effectively and responsibly create impact through corporate donations and grants
- Actively encourage employees to volunteer for organizations which support causes they care about and create systems and channels to quantify and showcase this work throughout the company

IN THIS SECTION

Corporate Giving Program

The Cytokinetics Corporate Giving Program, now in its second year, was established to better align and focus our charitable contributions to match our mission and values. Eligible recipients are U.S.-based nonprofit organizations working in three areas:

- Diversity in Science Education — Advancing science, technology, engineering and math (STEM) education for traditionally underrepresented students
- Health Equity in Cardiovascular Disease — Boosting health initiatives that address health inequities for cardiovascular disease (CVD) in underserved communities
- Local Community Support — Providing essential services to help address food and housing insecurity for at-risk populations to build stability and resilience

In 2025, the program provided funding ranging between $1,000 and $15,000 each to 19 organizations across our three focus areas.

> Our Corporate Giving philosophy is rooted in the power of partnering with non-profit organizations that can to make a lasting difference across our giving priorities with an emphasis on health equity in cardiovascular disease."

DIANE WEISER
SENIOR VICE PRESIDENT, CORPORATE AFFAIRS

Employee Volunteering

Rooted in the San Francisco Bay Area for more than 25 years, we believe it is essential to give back by supporting and engaging with our broader communities. We take pride in empowering and encouraging our employees to participate in community events, including volunteer opportunities, fundraisers and local and national awareness events that serve the communities we care about. By doing so, we hope to foster a strong connection between our company and the communities we call home.

In 2025, 204 employees volunteered more than 500 total hours supporting 9 community-based organizations. This includes our community outreach program partnering with science, technology, engineering and math (STEM)-related schools and nonprofit groups.

Cytokinetics employees volunteered with the following organizations in 2025:

- Life Science Cares Bay Area, Philadelphia and Switzerland
- City College of San Francisco Biotechnology Program
- Breakthrough San Francisco and Silicon Valley
- Carlmont High School Biotechnology Institute
- Expanding Your Horizons, U.C. Berkeley Chapter
- Career Readiness Program at U.C. Berkeley
- Scientific Adventures for Girls
- Community Resources for Science
- Habitat for Humanity

Employees participate in volunteering events throughout the year. In 2025, activities included serving meals at Samaritan House, assembling new parent kits with HealthRIGHT 360 and preparing STEM Kits for students.

Community Outreach

Our community outreach program is an important example of employee volunteerism. Through this companywide initiative, we team up with STEM-focused schools and nonprofit organizations' programs whose objectives support education and career development initiatives that can help increase diversity in the biotech industry.

In 2025, we partnered with 10 schools and nonprofit groups. Some of our employees serve as mentors for youth from underrepresented groups, helping them develop skills to reach their educational and career goals. Two of the organizations we continue to support are the San Francisco and Silicon Valley chapters of Breakthrough Collaborative, which works with traditionally underrepresented students to achieve postsecondary success and empowers aspiring leaders to become the next generation of educators and advocates.

OPERATING RESPONSIBLY FOR A SUSTAINABLE FUTURE

Cytokinetics is building responsible, resilient operations that support patients, employees and communities while preparing to operate effectively at global scale.

Our approach is grounded in strong governance, disciplined execution and continuous improvement across supply chain and facility operations. In supplier selection and oversight, we prioritize quality, compliance, reliability and shared values, with defined procurement criteria and cross-functional review. In our facilities, environmental sustainability priorities focus on data-informed actions to improve efficiency, reduce waste and responsibly manage energy and resources. The employee-led Sustainability Committee advances progress through practical initiatives. In parallel, we are improving systems and data collection to guide decision-making and reporting on climate impact and risk.

MATERIAL TOPICS

- Sustainable supply chain
- Employee health and safety
- Climate change risk management
- Emissions, Waste, Water

0.31
RECORDABLE INJURY RATE (RIR)
(PER 200,000 HOURS WORKED)

1300
POUNDS OF LAB PLASTICS RECYCLED

KEY ACCOMPLISHMENTS

- Established Global Supply Chain and Quality Operations Center of Excellence in Dublin
- Continued tracking and reporting of Scopes 1 and 2 GHG emissions for U.S. facilities
- Diverted 1300 pounds of lab plastics through recycling partnership with Polycarbin

2026 PRIORITIES

- Advance supplier code of conduct governance and oversight
- Establish Scope 3 emissions baseline for air and rail travel and corporate vehicle fleet
- Define and maintain internal standards to guide energy and water efficiency and waste reduction practices across all offices

IN THIS SECTION

SUPPLY CHAIN INTEGRITY AND SUSTAINABILITY

Under the direction of the Senior Vice President, Global Supply Chain and Technical Operations (GSC&TO), we manage a broad supplier portfolio to serve our late-stage pipeline and commercial products. Whether our suppliers are long-standing or new to Cytokinetics, we expect them to be materially aligned with the foundational elements of our corporate responsibility priorities.

> We have a solid plan, an outstanding global team, and the infrastructure in place. This year was about staying ready and preparing to operate at commercial scale."

STEVE COOK
SENIOR VICE PRESIDENT, GLOBAL SUPPLY CHAIN & TECHNICAL OPERATIONS

Our Supply Chain sourcing process includes a balanced scorecard that ranks potential vendors on a range of technical, performance, and values-oriented qualifications, including commitment to patient centricity, environmental and energy consciousness and community involvement.

The Supply Chain team plays a central role in ensuring that medicines can be reliably manufactured, released and delivered to patients worldwide. Working in close partnership with Cytokinetic's Regulatory and Quality teams, GSC&TO oversees the systems, processes, and external partnerships required to support compliant, efficient, and resilient product supply across all stages of commercialization. As the company prepares for its first global launches, Supply Chain is responsible for building the operational foundation that will enable Cytokinetics to meet future demand and uphold its commitments to patients.

Supplier Code of Conduct

Cytokinetics drafted a formal Supplier Code of Conduct in 2024, outlining expectations for ethics, compliance, quality, labor and human rights, health and safety, data privacy and security, accountability and environmental impact. The Code is designed to guide supplier engagement and serve as part of a risk-based framework for evaluating both new and existing partners. Intended for pilot deployment in 2025, implementation has been deferred as the Supply Chain organization focused on preparing for first commercial launches and building the systems and global capabilities necessary to support them. We plan to advance our Supplier Code of Conduct following key launch activities in 2026.

Global Supply Chain and Quality Operations Center of Excellence

In 2025, Cytokinetics established a new Global Supply Chain and Quality Operations Center of Excellence in Dublin, marking a major milestone in the company's transition to global commercial operations. Opened in October 2025, the center serves as the hub for supply chain, technical operations and quality activities supporting product launches across the U.S., Europe and China.

The office is staffed by a team bringing deep expertise in navigating global logistics, compliance requirements and multi-market product distribution. The Dublin team successfully advanced key operational systems, including completing the initial build of our enterprise resource planning (ERP) system and master data setup, positioning the organization to operate at global scale.

Members of the Dublin team meet with Fady Malik, Executive Vice President of Research & Development

WORKPLACE SAFETY

Cytokinetics is dedicated to providing a safe and healthy workplace for all employees and contractors. Workplace safety is approached as a shared responsibility, supported by robust programs, consistent training, and proactive risk management across laboratories, offices, and remote environments.

> We are ensuring that our training program is robust and consistent across sites—whether you're in a lab, office, or remote."

DEEPA RAMACHANDRA
ASSOCIATE EHS DIRECTOR

Environmental Health & Safety (EH&S) oversight

The Workplace Safety Program is managed by the Facilities and Environmental Health & Safety (EH&S) Department, which oversees safety policies, compliance and continuous improvement. EH&S leads quarterly reviews of incidents, regulatory inspections, training completion and changes that may impact laboratory or office safety. The department also oversees the Lab Safety Committee, which meets quarterly and includes representatives from all Cytokinetics laboratories to share insights, address risks and reinforce a strong culture of safety.

Each laboratory appoints a rotating Lab Captain annually. Lab Captains lead inspections, participate in the Lab Safety Committee, and promote cross-functional knowledge sharing, strengthening engagement and accountability at the local level.

Safety systems and training

Cytokinetics maintains an all-digital EH&S management system to track inspections, incidents, and corrective actions. Standard operating procedures outline clear roles and responsibilities for employees, managers, EH&S and Human Resources, including requirements for incident reporting and response. A business continuity plan supports preparedness through defined action plans and communication templates for internal and external stakeholders. Workplace safety training is tailored to role and location. Mandatory programs include video-based workplace violence prevention training for California-based employees.

2025 SAFETY HIGHLIGHTS

- In 2025, Cytokinetics strengthened and standardized safety training across sites. Onboarding and annual EH&S training were expanded using Vector Solutions and integrated into the *Thrive* learning system. New training modules addressed driver safety for expanding field teams, hazard awareness for office and laboratory employees and incident management across all locations.
- We successfully rolled out Hazardous Waste Awareness Training for all non-lab, office-based employees at our South San Francisco site. This initiative strengthens sitewide safety culture and supports our corporate responsibility goals. The goal of this initiative is to increase awareness, promote responsible waste management, and ensure compliance with environmental and workplace safety regulations, demonstrating our proactive approach to fostering a safe and environmentally responsible workplace.
- EH&S oversight was extended to European offices in Zug, Switzerland and Dublin, Ireland, with standardized European risk assessments and office safety protocols.
- The company also introduced an EH&S Change Management Process to review new equipment for safety, personal protective equipment, waste handling and training prior to use.
- Additional initiatives included the development of potent compound handling guidelines, expanded biological and chemical risk assessments and department-level risk assessments to identify task-based hazards.

ENVIRONMENTAL SUSTAINABILITY

Cytokinetics approaches environmental sustainability through practical, operations-focused actions that emphasize efficiency, responsible resource use and continuous improvement across facilities and day-to-day activities.

Cytokinetics facilities

Since occupying our South San Francisco corporate headquarters in 2022, we have maintained baseline data to support monitoring of facility-related greenhouse gas (GHG) emissions and resource consumption. The building, which is certified LEED Gold Core & Shell, is benchmarked through the EPA Energy Star Portfolio Manager by our property management company. Under the guidance of a leading carbon analytics consultant, we continue to strengthen our environmental performance.



Energy conservation measures—including HVAC scheduling and temperature setbacks during non-business hours—have supported measurable reductions in both natural gas and electricity consumption, reinforcing the value of incremental, data-informed operational improvements and savings. Solid waste disposal, along with the collection of compostable and recyclable materials, is tracked and reported by the local waste and recycling services provider. In 2025, 554 pounds of Styrofoam were recycled.

For our Radnor, Pennsylvania office, energy, water, and waste data are reported by the property management company. With two office locations in Europe, we are evaluating a longer-term approach to tracking and reporting environmental data, considering the scale and materiality of operations in regions where building systems are managed by third parties.

These charts represent key environmental performance measures tracked across our operations. Numbers are as of December 31 of applicable year. Reference the ESG Data Table in the Appendix for details.

Greenhouse Gas (GHG) Emissions (Metric tons CO2e)
Scope 1 and 2 (Location-based)

2023	2024	2025
1,459	1,254	1,283

Emissions Intensity (Scope 1 & 2) (tCO2e/employee)

2023	2024	2025
3.46	2.88	1.9

Electricity Use (MWh)

2023	2024	2025
4,509	4,392	4,812

Water Consumption (Million Gallons)

2023	2024	2025
1.488	1.497	1.55

Non-Hazardous Waste Disposal (Tons)

2023	2024	2025
87.60	81.67	81.67

Hazardous Waste Disposal (Tons)

2023	2024	2025
8.36	21.58	25.81

Sustainability Committee

The Sustainability Committee is composed of representatives from across business functions and advances three core goals: championing a culture of sustainability; managing general waste and reducing energy use; and reducing laboratory waste. The committee meets bimonthly to share ideas, assess options and report progress, with members responsible for advancing approved initiatives. Three senior leaders provide oversight, and the committee delivers annual updates to the Board as part of the company's corporate responsibility governance.

Closing the loop on laboratory plastics

In November 2024, Cytokinetics initiated a partnership with Polycarbin to recycle select laboratory plastics and nitrile gloves used in research labs. The vendor provides collection receptacles as well as delivery and pick-up services, extending the life cycle of lab products by remanufacturing them into new items. 1300 pounds of plastics have been collected since the program began.

Transportation emissions

As we expand our international operations and commercial activities, Cytokinetics is in the early stages of evaluating transportation-related emissions, including corporate air and rail travel and vehicle miles. Beginning in 2026, we look to establish initial baselines to better understand these impacts and inform future policies, purchasing decisions and reporting.

APPENDIX

IN THIS SECTION

PROGRESS TOWARD GOALS

The table below highlights our progress toward strategic goals, outlining key accomplishments and priorities across each focus area.

SCIENCE	PATIENTS	CULTURE	INTEGRITY	COMMUNITIES	OPERATIONS
Goal: • Maintain strong investment in innovative R&D programs rooted in unmet need and high scientific integrity	**Goals:** • Continually embed patient centricity across each stage of our business • Pursue equitable access and affordability of our medicines	**Goals:** • Foster a values-driven culture for a workplace that is safe, inclusive and rooted in excellence • Promote equitable, merit-based leadership development and advancement opportunities	**Goal:** • Continue to uphold integrity, ethics and compliance across the full range of business operations	**Goal:** • Champion health, education and resilience in the communities where we live and work	**Goals:** • Strengthen supply chain resilience through fair, competitive sourcing that encourages participation from a diverse, qualified supplier base • Advance environmental and climate risk management, integrating energy, water and waste considerations
Key Accomplishments: • Received approval of MYQORZO™ (*aficamten*) for treatment of oHCM in the U.S. and China and a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency • Successfully completed global regulatory inspections • Announced positive results of MAPLE-HCM	**Key Accomplishments:** • Published Plain Language Summary of primary results from SEQUOIA-HCM to make scientific data more accessible to a lay audience • Launched HCM Champions program to scale meaningful, compliant patient engagement • Designed MYQORZO & You patient support program in collaboration with patient community	**Key Accomplishments:** • Onboarded Cardiovascular Account Specialists with emphasis on shared culture and values • Established programs for mentorship, transformational leadership and change management training • Hired head of HR for Europe and extended EH&S oversight to European offices	**Key Accomplishments:** • Prepared for launch of MYQORZO™ (*aficamten*) in compliance with regulatory requirements • Completed annual training for 100% of employees on Code of Ethics and Business Conduct including new and updated policies • Enacted AI Governance program to support leadership in responsible evaluation and adoption of specialized AI tools	**Key Accomplishments:** • Completed second year of Corporate Giving Program, supporting 19 nonprofit organizations focused on science education, access to healthcare for cardiovascular disease and local at-risk communities • Supported employees in volunteering more than 500 hours	**Key Accomplishments:** • Established Global Supply Chain and Quality Operations Center of Excellence in Dublin • Continued tracking and reporting of Scopes 1 and 2 GHG emissions for U.S. facilities • Diverted 1300 pounds of lab plastics through recycling partnership with Polycarbin
2026 Priorities: • File Supplemental New Drug Application (sNDA) for *aficamten* based on results from MAPLE-HCM • Continue to advance six ongoing clinical stage programs including three with active enrollment • Pursue discovery of at least two investigational new drugs (INDs) to enter clinic in 2027 • Develop and enact diversity plans as integral part of clinical trial design	**2026 Priorities:** • Continue to engage patient populations in drug development process and collaborative design of patient resources • Increase education, awareness and patient resources by maintaining and expanding relationships with advocacy organizations • Evaluate and refine patient support and access programs based on post-launch metrics and feedback	**2026 Priorities:** • Build a future-ready leadership bench through talent development and mentorship • Prioritize organizational excellence including rollout of DARE decision-making framework • Listen to and engage employees to strengthen company culture as we grow and expand • Continue global integration of employee experience with new country culture leads	**2026 Priorities:** • Continue evolving compliance, data privacy and information security policies, practices and systems as operations expand globally • Continue supporting teams in evaluating responsible implementation of AI tools across business functions	**2026 Priorities:** • Continue to evaluate ways to effectively and responsibly create impact through corporate donations and grants • Actively encourage employees to volunteer for organizations which support causes they care about and create systems and channels to quantify and showcase this work throughout the company	**2026 Priorities:** • Advance supplier code of conduct governance and oversight • Establish Scope 3 emissions baseline for air travel and corporate vehicle fleet • Define and maintain internal standards to guide energy and water efficiency and waste reduction practices across all offices

ESG DATA TABLE

This table highlights key metrics reported year over year across ESG topics including environmental, workplace safety and data privacy. The data represents full-year 2025 performance.

As of December 31 of applicable year	2022	2023	2024	2025
Business Overview				
Total Revenue (USD, millions)	94.6	7.5	18.5	88.0
Investment in Research & Development (USD, millions)	241	330	339	416
SOCIAL				
Workforce				
Total Employees	400	420	497	673
Retention Rate (%)				
Turnover Rate	9%	10.6%	11%	10.1%
Voluntary Turnover Rate	6%	3.6%	4%	5.1%
Employee Engagement Score (%)	--	8.2	8.0	8.1
Workplace Health and Safety				
Recordable Injury Rate (RIR) (per 200,000 hours worked)	--	0.23	0.89	0.31
Lost Time Injury Rate (LTIR) (per 200,000 hours worked)	--	0	0.22	0
Fatalities	--	0	0	0
Community Impact				
Corporate Contributions [1] (USD, millions)	--	2	2.9	2.7
Employee Volunteer Hours (estimate)	--	555	450	500
GOVERNANCE				
Board Composition [2]				
Board Size	10	10	10	10
Number of Independent Directors	9	9	9	9

	2022	2023	2024	2025
ENVIRONMENT				
Greenhouse Gas (GHG) Emissions (Metric tons CO_2e)				
Scope 1 (fuels, natural gas, refrigerants)	642	421	242	294
Scope 2 (electricity use) (Market-based)	--	--	540	630
Total Scope 1 and 2 (Market-based)	--	--	**782**	**924**
Emissions Intensity (Scope 1 and 2) (tCO_2e/employee) [3]	--	--	*1.8*	*1.4*
Scope 2 (electricity use) (Location-based)	830	1,038	1,012	989
Total Scope 1 and 2 (Location-based)	**1,472**	**1,459**	**1,254**	**1,283**
Emissions Intensity (Scope 1 and 2) (tCO_2e/employee) [3]	*3.56*	*3.47*	*2.88*	*1.9*
Scope 3 (air and rail travel and employee commute) [4]	--	--	--	2,530
Electricity Use (MWh) (by source)				
Total electricity use from non-renewable sources	--	2,370	2,311	2,628
Total electricity use from renewable sources	--	2,139	2,081	2,183
Total Electricity Use (MWh) [5]	--	**4,509**	**4,392**	**4,812**
Total Water Consumption (Million Gallons)	**0.995**	**1.488**	**1.497**	**1.55**
Non-Hazardous Waste Disposal (Tons) [6]				
Landfilled	--	27.05	25.75	25.75
Recycled	--	27.41	19.35	19.35
Composted	--	33.14	36.57	36.57
Total Non-Hazardous Waste Disposal (Tons)	--	**87.60**	**81.67**	**81.67**
Hazardous Waste Disposal (Tons) [6]				
Landfilled	13.20	14.79	18.07	21.58
Recycled	0.02	3.57	3.51	4.23
Total Hazardous Waste Disposal (Tons)	**13.22**	**18.36**	**21.58**	**25.81**

1 Includes grants, sponsorships and philanthropic donations
2 As of April 8 of applicable year (per proxy filing)
3 Emissions intensity calculated using the average number of employees for the year, which was 435 in 2024 and 673 in 2025
4 Scope 3 emissions baseline (market-based) calculated from 2025 business travel data and employee commute estimates based on employee headcount, using standardized assumptions and emission factors to approximate commuting patterns.
5 Electricity for Cytokinetics South San Francisco facilities is purchased through Peninsula Clean Energy with 50% from renewable sources.
6 Cytokinetics South San Francisco facilities only

SASB INDEX

The following table provides data and information for Cytokinetics utilizing the Sustainable Accounting Standards Board's (SASB) Health Care Sector - Biotechnology and Pharmaceuticals industry standard (2018-10). The data represents full-year 2025 performance.

Category	Code	Accounting Metric	Information
Safety of Clinical trial participants	**HC-BP210a.1**	Discussion, by world region, of management process for ensuring quality and patient safety during clinical trials	For details, see **Clinical trials**
	HC-BP-210a.2	Number of FDA sponsor inspections related to clinical trial management and pharmacovigilance that resulted in 1) Voluntary Action Indicated (VAI) and 2) Official Action Indicated (OAI)	No sponsor inspections related to clinical trial management and pharmacovigilance resulted in VAI or OAI
	HC-BP-210a.3	Total amount of monetary losses as a result of legal proceedings associated with clinical trials in developing countries	None
Access to Medicines	**HC-BP-240a.1**	Description of action and initiatives to promote access to health care products for priority diseases and in priority countries as defined by the Access to Medicine Index	N/A
	HC-BP-240a.2	List of products on the WHO List of Prequalified Medicinal Products as part of its Prequalification of Medicines Programme (PQP)	N/A
Affordability & Pricing	**HC-BP-240b.1**	Number of settlements of Abbreviated New Drug Application (ANDA) litigation that involved payments and/or provisions to delay bringing an authorized generic product to market for a defined time period	N/A
	HC-BP-240b.2	Percentage change in 1) average list price and 2) average net price across US product portfolio from previous year	N/A
	HC-BP-240b.3	Percentage change in 1) list price and 2) net price of product with largest increase compared to previous year	N/A
Drug Safety	**HC-BP-250a.1**	List of products listed in the FDA MedWatch Safety Alerts for Human Medical Products database	No products listed. Please visit the **FDA FAERS MedWatch website** for more information
	HC-BP-250a.2	Number of fatalities associated with products as reported in the FDA AERS	None. Please visit the **FDA FAERS MedWatch website** for more information
	HC-BP-250a.3	Number of recalls issued, total units recalled	N/A
	HC-BP-250a.4	Total amount of product accepted for takeback, reuse, or disposal	N/A
	HC-BP-250a.5	Number of FDA enforcement actions taken in response to violations of current Good Manufacturing Practices (cGMP), by type	N/A

SASB INDEX (CONTINUED)

Category	Code	Accounting Metric	Information
Counterfeit Drugs	**HC-BP-260a.1**	Description of methods and technologies used to maintain traceability of products throughout the supply chain and prevent counterfeiting	N/A
	HC-BP-260a.2	Discussion of process for alerting customers and business partners of potential or known risks associated with counterfeit products	N/A
	HC-BP-260a.3	Number of actions that led to raids, seizure, arrests, and/or filing of criminal charges related to counterfeit products	None
Ethical Marketing	**HC-BP-270a.1**	Total amount of monetary losses as a result of legal proceedings associated with false marketing claims	No losses related to false claims
	HC-BP-270a.2	Description of code of ethics governing promotion of off-label use of products	N/A
Employee Recruitment, Development & Retention	**HC-BP-330a.1**	Discussion of talent recruitment and retention efforts for scientists and research and development personnel	For details, see **Culture**
	HC-BP-330a.2	1) Voluntary and 2) Involuntary turnover rate for (a) executive/senior managers, (b) mid-level managers, (c) professionals, and (d) all others	Average employee turnover in 2025 was 10.1% and voluntary turnover was 5.1%. Voluntary turnover rate for each of the following groups was: executive/senior managers (2.7%), mid-level managers (1.5%), and professionals (0.9%). Involuntary turnover rate for each of the following groups was: executive/senior managers (1.34%), mid-level managers (1.93%), and professionals (0.45%).
Supply Chain Management	**HC-BP-430a.1**	Percentage of (1) entity's facilities and (2) Tier I suppliers' facilities participating in the Rx-360 International Pharmaceutical Supply Chain Consortium audit program or equivalent third-party audit program for integrity of supply chain and ingredients	Not reported
Business Ethics	**HC-BP-510a.1**	Total amount of monetary losses as a result of legal proceedings associated with corruption and bribery	Zero
	HC-BP-510a.2	Description of code of ethics governing interactions with health care professionals	For details, see **Governance, Ethics and Compliance**
Activity Metrics	**HC-BP-000.A**	Number of patients treated	As of the end of 2025, no patients had been prescribed approved medicine. All other products are in the investigational stage.
	HC-BP-000.B	Number of drugs in portfolio and research and development (Phase 1-3)	Visit **cytokinetics.com/pipeline** for the latest review of therapies in development

GRI CONTENT INDEX

Cytokinetics has reported the information cited in this GRI content index for the period January 1, 2025 to December 31, 2025 with reference to the GRI Standards. For more information about the Global Report Initiative, visit **globalreporting.org**

GRI 1 used:
GRI 1: Foundation 2021

GRI Standard	Disclosure	Location
GRI 2: General Disclosures 2021	2-1 Organizational details	About Cytokinetics
	2-2 Entities included in the organization's sustainability reporting	Cytokinetics, Inc.
	2-3 Reporting period, frequency and contact point	About this report
	2-4 Restatements of information	Not applicable
	2-5 External assurance	None
	2-6 Activities, value chain and other business relationships	About Cytokinetics, Our Areas of Focus
	2-7 Employees	ESG Data Table
	2-8 Workers who are not employees	446
	2-9 Governance structure and composition	Governance, Ethics and Compliance
	2-10 Nomination and selection of the highest governance body	https://ir.cytokinetics.com/governance
	2-11 Chair of the highest governance body	Governance, Ethics and Compliance
	2-12 Role of the highest governance body in overseeing the management of impacts	Governance, Ethics and Compliance
	2-13 Delegation of responsibility for managing impacts	Governance, Ethics and Compliance
	2-14 Role of the highest governance body in sustainability reporting	Corporate Responsibility Governance
	2-15 Conflicts of interest	Code of Ethics and Business Conduct
	2-16 Communication of critical concerns	Ethics and compliance hotline
	2-17 Collective knowledge of the highest governance body	Corporate Responsibility Governance
	2-18 Evaluation of the performance of the highest governance body	https://ir.cytokinetics.com/governance
	2-19 Remuneration policies	https://ir.cytokinetics.com/governance
	2-20 Process to determine remuneration	https://ir.cytokinetics.com/governance
	2-21 Annual total compensation ratio	See Proxy statement: Principal Executive Officer Pay Ratio
	2-22 Statement on sustainable development strategy	Introduction, Progress Toward Goals

GRI CONTENT INDEX (CONTINUED)

GRI Standard	Disclosure	Location
	2-23 Policy commitments	Code of Ethics and Business Conduct, Alignment to PhRMA Code
	2-24 Embedding policy commitments	Code of Ethics and Business Conduct, Supplier Code of Conduct
	2-25 Processes to remediate negative impacts	Not reported
	2-26 Mechanisms for seeking advice and raising concerns	Ethics and compliance hotline
	2-27 Compliance with laws and regulations	Code of Ethics and Business Conduct
	2-28 Membership associations	Not reported
	2-29 Approach to stakeholder engagement	Patient and Caregiver Advisory Councils, Employee engagement
	2-30 Collective bargaining agreements	Not applicable
GRI 3: Material Topics 2021	3-1 Process to determine material topics	Materiality
	3-2 List of material topics	Materiality
	3-3 Management of material topics	Progress Toward Goals
GRI 102: Climate Change 2025	102-5 Scope 1 GHG emissions	ESG Data Table
	102-6 Scope 2 GHG emissions	ESG Data Table
	102-7 Scope 3 GHG emissions	Not reported
	102-8 GHG emissions intensity	ESG Data Table
GRI 103: Energy 2025	103-1 Energy policies and commitments	Environmental Sustainability
	103-2 Energy consumption and self-generation within the organization	ESG Data Table
	103-3 Upstream and downstream energy consumption	Not reported
	103-4 Energy intensity	Not reported
	103-5 Reduction in energy consumption	Cytokinetics facilities, ESG Data Table

GRI CONTENT INDEX (CONTINUED)

GRI Standard	Disclosure	Location
GRI 201: Economic Performance 2016	201-1 Direct economic value generated and distributed	ESG Data Table
	201-3 Defined benefit plan obligations and other retirement plans	Not applicable
	201-4 Financial assistance received from government	None
GRI 205: Anti-corruption 2016	205-2 Communication and training about anti-corruption policies and procedures	Compliance training
	205-3 Confirmed incidents of corruption and actions taken	In 2025, there were no findings of corruption, anti-competitive behavior, violations of anti-trust and monopoly legislation, or other healthcare compliance violations from any government body.
GRI 301: Materials 2016	301-1 Materials used by weight or volume	Not reported
	301-2 Recycled input materials used	Not reported
	301-3 Reclaimed products and their packaging materials	Not reported
GRI 303: Water and Effluents 2018	303-5 Water consumption	ESG Data Table
GRI 306: Waste 2020	306-1 Waste generation and significant waste-related impacts	ESG Data Table
	306-2 Management of significant waste-related impacts	Environmental Sustainability
	306-3 Waste generated	ESG Data Table
	306-4 Waste diverted from disposal	ESG Data Table
	306-5 Waste directed to disposal	ESG Data Table
GRI 308: Supplier Environmental Assessment 2016	308-1 New suppliers that were screened using environmental criteria	Supply Chain Integrity and Sustainability
	308-2 Negative environmental impacts in the supply chain and actions taken	Not reported
GRI 401: Employment 2016	401-1 New employee hires and employee turnover	ESG Data Table
	401-2 Benefits provided to full-time employees that are not provided to temporary or part-time employees	Wellness and Benefits Program
	401-3 Parental leave	Wellness and Benefits Program

GRI CONTENT INDEX (CONTINUED)

GRI Standard	Disclosure	Location
GRI 403: Occupational Health and Safety 2018	403-1 Occupational health and safety management system	Workplace Safety
	403-2 Hazard identification, risk assessment, and incident investigation	Workplace Safety
	403-3 Occupational health services	Workplace Safety
	403-4 Worker participation, consultation, and communication on occupational health and safety	Workplace Safety
	403-5 Worker training on occupational health and safety	Workplace Safety
	403-6 Promotion of worker health	Workplace Safety, Wellness and Benefits Program
	403-7 Prevention and mitigation of occupational health and safety impacts directly linked by business relationships	Not reported
	403-8 Workers covered by an occupational health and safety management system	Workplace Safety
	403-9 Work-related injuries	ESG Data Table
	403-10 Work-related ill health	ESG Data Table
GRI 404: Training and Education 2016	404-1 Average hours of training per year per employee	Not reported
	404-2 Programs for upgrading employee skills and transition assistance programs	*Thrive* talent development hub
	404-3 Percentage of employees receiving regular performance and career development reviews	Performance management
GRI 405: Diversity and Equal Opportunity 2016	405-1 Diversity of governance bodies and employees	Not reported
	405-2 Ratio of basic salary and remuneration of women to men	Not reported
GRI 406: Non-discrimination 2016	406-1 Incidents of discrimination and corrective actions taken	Not reported
GRI 413: Local Communities 2016	413-1 Operations with local community engagement, impact assessments, and development programs	Not reported
GRI 414: Supplier Social Assessment 2016	414-1 New suppliers that were screened using social criteria	Supplier Code of Conduct
	414-2 Negative social impacts in the supply chain and actions taken	Not reported
GRI 415: Public Policy 2016	415-1 Political contributions	None
GRI 416: Customer Health and Safety 2016	416-1 Assessment of the health and safety impacts of product and service categories	Research and Development, Clinical Trials
	416-2 Incidents of non-compliance concerning the health and safety impacts of products and services	None

GRI CONTENT INDEX (CONTINUED)

GRI Standard	Disclosure	Location
GRI 417: Marketing and Labeling 2016	417-1 Requirements for product and service information and labeling	Instructions for the safe use of our medicine are included in the downloadable Prescribing Information and Patient Information documents on our website. **cytokinetics.com/our-medicine/**
	417-2 Incidents of non-compliance concerning product and service information and labeling	Cytokinetics did not receive from any government body any warnings, fines or penalties in 2025 related to our labeling practices.
	417-3 Incidents of non-compliance concerning marketing communications	Cytokinetics did not receive from any government body any warnings, fines or penalties in 2025 related to our marketing communications
GRI 418: Customer Privacy 2016	418-1 Substantiated complaints concerning breaches of customer privacy and losses of customer data	Cytokinetics did not have any substantiated complaints concerning losses of customer data in 2025.

NOTES

1 Ommen SR, Ho CY, Asif IM, et al. 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2024;149(23):e1239-e1311. doi:10.1161/CIR.0000000000001250.

2 Ho CY, Day SM, Ashley EA, et al. Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe). Circulation. 2018;138(14):1387-1398. doi:10.1161/CIRCULATIONAHA.117.033200.

3 James et al. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Lancet 2018; 392: 1789–858.

4 Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA Guideline for the Management of Heart failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;128:e240-e327.

5 Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129–2200.

6 Roger VL. Epidemiology of Heart Failure. Circulation Research. 2013;113:646-659, originally published August 29, 2013. doi: 10.1161/CIRCRESAHA.113.300268.

7 Kilgore M, Patel HK, Kielhorn A, et al. Economic burden of hospitalizations of Medicare beneficiaries with heart failure. Risk Manag Healthc Policy. 2017; 10: 63-70.

8 Taylor C J, Ordóñez-Mena J M, Roalfe A K, et al. Trends in survival after a diagnosis of heart failure in the United Kingdom 2000-2017: population based cohort study. BMJ 2019; 364:l223 doi:10.1136/bmj.l223

9 Greene SJ, Bauersachs J, Brugts JJ, et al. Worsening Heart Failure: Nomenclature, Epidemiology, and Future Directions: JACC Review Topic of the Week. JACC. 2023 Jan 31;81(4):413-424. doi:10.1016/j.jacc.2022.11.023. PMID: 36697141.

10 Extrapolated from Desai NR, Butler J, Binder G, et al. Prevalence and Excess Risk of Hospitalization in Heart Failure with Reduced Ejection Fraction. Poster presented at: Heart Failure Society of America (HFSA) Annual Scientific Meeting; 2022 Sep 30-Oct 3; Washington, DC.

11 Carnicelli AP, Clare RM, Hofmann P, et al. Clinical trajectory of patients with a worsening heart failure event and reduced ventricular ejection fraction. Am Heart J. 2022 Mar; 245:110-116. doi: 10.1016/j.ahj.2021.12.003. Epub 2021 Dec 18. PMID: 34932997.

IMPORTANT SAFETY INFORMATION

WARNING: RISK OF HEART FAILURE

MYQORZO reduces left ventricular ejection fraction (LVEF) and can cause heart failure due to systolic dysfunction.

Echocardiogram assessments are required prior to and during treatment with MYQORZO to monitor for systolic dysfunction. Initiation of MYQORZO in patients with LVEF <55% is not recommended. Decrease the dose of MYQORZO if LVEF is <50% and ≥40%. Interrupt the dose of MYQORZO if LVEF <40% or if the patient experiences heart failure symptoms or worsening clinical status due to systolic dysfunction.

Because of the risk of heart failure due to systolic dysfunction, MYQORZO is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the MYQORZO REMS Program.

Forward-Looking Statements

This report contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements, expressed or implied, relating to: the potential regulatory approval of *aficamten* or any other drug candidate in any indication or jurisdiction, including potential approvals based on results from ACACIA-HCM or any other clinical trial; the ability to successfully launch and expand commercialization of MYQORZO or any future approved product in the United States, Europe, China, Japan or any other jurisdiction; the ability to achieve commercial uptake of MYQORZO or any future approved product among any targeted number of healthcare professionals, patients or in any targeted number of jurisdictions; the initiation, conduct, enrollment, progress, timing and results of any ongoing or planned clinical trials, including ACACIA-HCM, CEDAR-HCM, COMET-HF, AMBER-HFpEF and any other clinical programs; the ability to advance any drug candidate into clinical development, including the advancement of any targeted number of investigational new drug candidates into clinical trials by any specified date; the ability to expand Cytokinetics' research platform through new therapeutic modalities, including targeted protein degraders, oligonucleotides and tissue targeting, or through the use of artificial intelligence and other emerging technologies; the ability to achieve any environmental, sustainability or emissions targets or goals, including the establishment of greenhouse gas emissions baselines or the implementation of energy, water and waste reduction initiatives; and the ability to achieve any of the strategic objectives set forth in the company's Vision 2030 plan, including with respect to the number of approved products, indications, pipeline candidates, patients treated or jurisdictions in which the company's medicines are available.

Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, the risks related to Cytokinetics' business outlined in Cytokinetics' filings with the Securities and Exchange Commission, particularly under the caption "Risk Factors" in Cytokinetics' most recent Annual Report on Form 10-K and subsequent quarterly reports on Form 10-Q. Forward-looking statements are not guarantees of future performance, and Cytokinetics' actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this report. Any forward-looking statements that Cytokinetics makes in this report speak only as of the date of this report. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this report. Issues identified as material, significant, key or priority for purposes of, and information otherwise included in, this document are not an indication that they are considered material to us, our investors, or other stakeholders, or that they are required to be disclosed in our filings under the U.S. Securities and Exchange Commission reporting or any other applicable laws or requirements.

Commercial Product Disclaimer

This report is intended for stakeholder use only and is not for promotional purposes. For information about Cytokinetics products referenced in this report, please review the full Prescribing Information available on Cytokinetics.com. Any investigational products or uses discussed in this report are not approved by the U.S. Food and Drug Administration, and their safety and efficacy have not been established.

On the front cover:
© The Trustees of Indiana University.
Photo provided courtesy of Indiana University Southeast, photography by Tony Bennett Photography.

Cytokinetics, Inc.
350 Oyster Point Blvd
South San Francisco, CA 94080
(650) 624-3000
investor@cytokinetics.com

Follow @cytokinetics

cytokinetics.com